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Abstract 
Purpose and Specific Aims: Anesthetic agents used for pregnant mothers have been 
evaluated in an attempt to improve the safety of maternal-fetal anesthesia. 
Dexmedetomidine (DEX; Precedex®), a potent and highly selective α2-adrenoceptor 
agonist approved by FDA in 1999 as a sedative, has been suggested to be suitable for 
maternal-fetal anesthesia. It offers significant sedative, analgesic and anxiolytic effects 
without causing respiratory depression. The mechanism of DEX action mediated by 
signaling pathways other than the α2-adrenoceptor has been reported to play a role in 
neuroprotection. Animal studies have indicated that DEX could provide neuroprotective 
effects on anesthetic-induced neurotoxicity in neonatal rats. However, the impact of 
maternal use of DEX that may be associated with hypotension and bradycardia on fetal 
development during pregnancy is not fully understood; this greatly limits its usage in 
pregnant women. 
Our proposed research has focused on the investigation of fetal exposure and response 
to the maternal use of DEX during pregnancy. In this study, pregnant ewe was selected 
as an experimental model due to the ethical issues in performing experiments on human 
fetuses. Pregnant ewe has been an extensively used model for human pregnancy due to 
its main advantage that the relatively large size of the fetus enables catheters 
implantation in both maternal and fetal blood vessels for repeated sampling.  
Towards our goal, three major specific aims were proposed to: (1) determine the DEX 
exposure and cardiovascular response in pregnant ewe and fetus, as well as the extent 
of placental transfer; (2) investigate the degree of plasma protein binding and UDP-
glucuronosyltransferase (UGT) metabolism in pregnant ewe and fetus; and (3) establish 
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pharmacokinetic (PK) model and pharmacodynamic (PD) model of cardiovascular 
effects in pregnant ewe and fetus.  
Methods: Surgeries and catheterizations were carried out on eight pregnant Western 
Cross ewes at the Texas Children’s Hospital, Baylor College of Medicine. Pregnant 
ewes received an initial 1 µg/kg loading infusion over 10 min followed by an intravenous 
(IV) infusion of 1 µg/kg/h for 1 h. Arterial and venous blood samples were collected at 10 
min up to 250 min from both pregnant ewe and fetus. Free and total DEX plasma 
concentrations were quantified by our developed and validated LC-MS/MS assay. Non-
compartmental PK analysis was performed to determine the partition coefficient from 
pregnant ewe to fetus (KFM), followed by the PK analysis using non-linear mixed effect 
(NLME) approach to describe the free and total DEX concentrations in the pregnant ewe 
and fetus. Maternal and fetal heart rates (HR) and arterial blood pressure (BP) were 
monitored. In vitro UGT metabolism studies with liver and placental microsomes were 
also conducted. 
Results: DEX concentrations in maternal artery and fetal vein were 815.1±497.2 and 
104.4±40.3 pg/mL at 10 min. KFM were 0.13 ± 0.10 and 0.23 ± 0.14 at 10 min and 250 
min, respectively. A two-compartment model with first-order elimination best described 
the maternal data. An effect compartment linked to maternal circulation by first-order 
processes adequately characterized fetal concentrations. The relationship between free 
and total concentrations was satisfactorily described by linear protein binding model. For 
cardiovascular effects, pregnant ewes demonstrated a 30-40% decrease in BP and 
significant bradycardia with a 42-49% decrease in HR. In contrast, hypotension was not 
observed and only a modest decrease in heart rate was noted in fetuses. In vitro 
metabolism studies found negligible DEX glucuronide metabolites after incubation for up 
to 24 h with hepatic and placental microsomes prepared from the pregnant ewe and 
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fetus. Differential UGT enzyme activity in hepatic microsomes between pregnant ewe 
and fetus was determined using genistein as a typical known UGT substrate. It was 
demonstrated that pregnant ewe has 17 times higher UGT enzyme capacity than that in 
the fetus. 
Conclusion and Significance: The contribution of our study is a better understanding 
of fetal exposure and cardiovascular response to maternal administration of DEX in 
pregnant ewes. We have demonstrated that 1) DEX can rapidly cross pregnant ewe 
placenta with KFM of 23% to fetuses; (2) administration of DEX to pregnant ewe does not 
result in fetal hypotension or significant bradycardia; (3) in pregnant ewe DEX undergoes 
rapid distribution and a relatively slow elimination after administration; (4) fetus has lower 
plasma protein binding than that in pregnant ewe based on results from PK modeling 
and in vitro assessments; (5) there is a differential UGT enzyme capacity between 
pregnant ewe and fetus; and (6) direct N-glucuronidation is a negligible metabolic 
pathway for DEX in pregnant ewe which differs from that in humans. Therefore, our 
findings in combination with other related publications support conducting additional 
DEX studies for its clinical utility during pregnancy, but pregnant ewe may not be a 
representative model for DEX phase II metabolism study in humans. Future 
physiological-based pharmacokinetic modeling for the prediction of human fetal 
exposure and response should be investigated.  
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Chapter 1 Literature Review 
 
 
1.1. Anesthesia for non-obstetric surgery 
Surgery unrelated to delivery during pregnancy is defined as non-obstetric surgery. 
Because of additional risk to the mother and children, this type of surgery should be 
avoided during pregnancy. Nevertheless, non-obstetric surgery may be performed 
during any stage of pregnancy depending on the urgent indications. Generally 0.75-2% 
of pregnant women require non-obstetric surgery during their pregnancy (Reitman E et 
al., 2011). Approximately 42%, 35% and 23% of non-obstetric surgeries were performed 
in the first, second and third trimesters of pregnancy, respectively (Mazze RI et al., 
1989). Each year more than 80,000 pregnant women undergo non-obstetric surgery in 
the U.S. (Goodman S et al., 2002). This number is growing continuously because of the 
advances in fetal and obstetric procedures. 
Safe anesthesia must be provided for both pregnant women and children during non-
obstetric surgery. During pregnancy, the women undergo profound physiological 
changes. These changes have been extensively reviewed in many textbooks and 
numerous reports in the literature (Cohen SE et al., 1999; Goodman S et al., 2002; Ní 
Mhuireachtaigh R et al., 2006; Cheek TG et al., 2009, Pacheco L et al., 2013; Costantine 
MM et al., 2014).  On the other hand, the maternal use of anesthetic agents, that may 
have direct or indirect effects on the fetuses, is less understood. The potential risk of 
drug teratogenic effects to the fetus that is associated with the intrinsic toxicity, as well 
as the dosage and duration of exposure should be avoided. Therefore, considerations 
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for the safety on both mother and fetuses are extremely necessary when we select the 
anesthetic drugs to ensure successful maternal and fetal outcomes.   
1.2. Physiological changes in pregnancy  
The physiological changes during pregnancy affect almost every organ system and 
influence the anesthetic and perioperative management of the pregnant women. Some 
of these changes, including in the respiratory, cardiovascular, gastrointestinal, and renal 
as well as nervous systems, might directly influence the pharmacokinetics (absorption, 
distribution, metabolism and elimination) of drugs. These changes are primarily caused 
by the profound increases in hormone concentrations. Apart from increased 
concentration of hormones, other factors such as increased metabolic demand, 
mechanical effects of an enlarged uterus and presence of the low resistance placental 
circulation play important roles in physiological changes in pregnancy. 
1.2.1. Respiratory system changes 
Anesthesiologists are concerned regarding the clinically relevant changes in respiratory 
physiology due to the use of anesthesia in pregnancy. Several physiological alterations 
in the respiratory system make pregnant women susceptible to develop hypoxemia 
(Mahli A et al., 2000).  
During pregnancy, observed reduction in PaO2 in pregnant women is due to increased 
oxygen consumption and decreased pulmonary functional residual capacity (Hegewald 
MJ et al., 2011). Maternal obesity and/or preeclampsia could accentuate the risk of 
hypoxemia related to the induction of general anesthesia. Progesterone enhances 
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brainstem activity to PaCO2 leading to maternal hyperventilation, which is hindered by 
greater CNS sensitivity to general anesthetics in the anaesthetized patient. 
Pregnancy could also result in anatomic changes in the airway, including swelling and 
friability of oropharyngeal tissues which ultimately lead to the significant reduction of the 
glottic opening near the end term of pregnancy. These changes have been observed 
since the mid-second trimester and become most pronounced before delivery. 
Physiological changes in the maternal airway can also make endotracheal intubation 
more difficult, which increases the risk of failed intubation. Failed intubation is the 
primary cause of death related to anesthesia (Kuczkowski KM et al., 2003). 
1.2.2. Changes in cardiovascular and hematologic systems 
Early in the first trimester during pregnancy, cardiac output starts to increase and is 
elevated approximately by 50% of non-pregnant values by the end of the second 
trimester (Capeless EL et al., 1989). This results from both an increase in heart rate (by 
about 25%) and stroke volume (by about 30%) (Clark SL et al., 1989). This increase in 
cardiac output is necessary because of the high metabolic demands of fetuses.  
Minor changes occur in blood pressure during pregnancy. It falls down slightly in the first 
trimester, increases during the second trimester, and returns to approximately its pre-
pregnancy level in the third trimester. Usually, blood volume expands in the first 
trimester by 35-50% (Cohen SE et al., 1999). The increased blood volume associated 
with red cell mass results in physiologic anemia and hemodilution. This particular 
physiologic function might provide protection to women during pregnancy as well as lead 
to increased red cell mass coupled with increased uterine blood flow, optimizing oxygen 
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transport to the fetus (Pacheco L et al., 2013). The reduction in blood viscosity is also 
another reason for improvement of flow through the utero-placental circulation. 
During pregnancy, some significant changes in the coagulation and fibrinolytic pathway, 
such as elevated plasma circulating levels of clotting factors (VII, VIII, IX, X, and XII), 
fibrinogen and platelet turnover are observed. Though fibrinolysis produces the 
hypercoagulable state which places pregnant women at high risks of experiencing 
thromboembolic events, it also provides a survival advantage by minimizing blood loss in 
the postoperative period or after delivery (Hellgren M et al., 1996).  
1.2.3. Gastrointestinal system changes 
Pregnant women have been considered to experience delayed gastric emptying, 
prolonged intestinal transit time, decreased lower esophageal sphincter tone and slightly 
increased gastric acidity. They were thought to be caused by both the endocrinologic 
factor of progesterone and the mechanical factor of an enlarging uterus. More recent 
data have suggested that pregnancy itself does not delay gastric emptying. Evidence 
has shown that except for laboring women, no significant delay in gastric emptying was 
demonstrated in the three trimesters of pregnancy compared to non-pregnant women 
(Macfie AG et al., 1991; Whitehead EM et al., 1993). In contrast, gastric motility 
decreases during active labor. 
During pregnancy increased gastric pressure along with the reduced resting muscle tone 
of the lower esophageal sphincter leads to an increased incidence of reflux esophagitis 
and heartburn which places pregnant women at increased risk for gastric acid aspiration 
in sedated/anesthetized conditions (after about 16 weeks' gestation) (Wong CA et al., 
2002).  
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1.2.4. Renal system changes 
In pregnancy, renal plasma flow and glomerular filtration rate (GFR) are both increased. 
As early as the first trimester, renal plasma flow and GFR increase by 50-80% and 40-
65%, respectively (Jeyabalan A et al., 2007). As a result, the renal clearance has 
increased by approximately 50% which leads to the increased renal excretion rate and 
consequentially decreased serum concentrations of creatinine, urea, and uric acid. 
Therefore, adjustment of dosages and administration schedules for anesthesia is 
necessary in order to compensate for these changes. During pregnancy, the renal 
glucose threshold decreases which can produce glucosuria. However, sodium excretion 
remains normal (Davison JM et al., 1980).  
1.2.5. Changes in central and peripheral nervous systems 
It is well known that pregnancy can change pharmacokinetic and pharmacodynamic of 
many drugs, lowering the required anesthetic dose. Pregnant women have 
demonstrated an approximately 30% reduction in the minimum alveolar concentrations 
for inhalation anesthetics (Gin T et al., 1994). Similarly, intravenous drugs that induce 
general anesthesia also are given in lower doses to pregnant women (Gin T et al., 
1997). Several studies have also demonstrated neural tissues are more sensitive to the 
effects of local anesthetic drugs in pregnant women compared to non-pregnant women, 
which results in reduced anesthetic doses and lower plasma concentrations during 
pregnancy (Sanson BJ et al., 1999).  
Several mechanisms including mechanical, biochemical and hormonal mechanisms, 
have been suggested to explain the phenomenon. Changes in inferior vena cava 
compression and epidural venous plexus cause the reduction of total volume of the 
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epidural and subarachnoid spaces, which may explain the decreased anesthetic 
requirement and extensive distribution of local anesthetic agents administered during 
central neuraxial blockade. 
In adult, the autonomic nervous system shows a biphasic response to the hemodynamic 
changes (e.g. blood pressure and heart rate). A published study has indicated that the 
autonomic nervous activity shifted towards a higher vagal tone and lower sympathetic 
activity along with elevated blood volume in the first trimester, and was altered towards a 
lower vagal tone and increased sympathetic activity in the third trimester. (Kuo CD et al., 
2000). 
1.2.6. Physiologically related PK changes 
Based on a comprehensive meta-analysis of data with healthy adult women, maternal 
physiology changes at each trimester during pregnancy that have direct influence on 
ADME/PK have been summarized in Table 1 (Ke AB et al., 2014).  
In short, these changes include previously discussed changes in (1) cardiovascular 
systems (cardiac output, stroke volume and heart rate); (2) hematologic systems 
(plasma volume, red blood cell volume and hematocrit as well as blood flow); (3) GI 
systems (gastric emptying and GI transit time); (4) renal systems (GFR, creatinine 
clearance) and (5) others, including body weight and body fat composition as well as 
albumin and α1-acid glycoprotein levels.  
Changes in liver enzyme activity during pregnancy also have significant effects on PK 
alterations in pregnant women comparing to the non-pregnant counterparts. These 
changes involve both phase I and phase II metabolic pathways. For example, enzyme 
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activity of CYP3A4 (Little BB et al., 1999) and UGT1A4 (de Haan GJ et al., 2004) both 
increased during pregnancy. 
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Table 1 Maternal physiology changes during pregnancy (Ke AB et al., 2014)  
Parameters 1st Trimester 2nd Trimester 3rd Trimester 
Total body weight (kg) 6% ↑ 16% ↑ 23% ↑ 
Total fat mass (kg) 11% ↑ 16% ↑ 32% ↑ 
Total body water (L) 11% ↑ 27% ↑ 41% ↑ 
Cardiac output (L) 18% ↑ 28% ↑ 33% ↑ 
Plasma volume (L) 7% ↑ 42% ↑ 50% ↑ 
Red blood cell volume (L) 4% ↑ 20% ↑ 28% ↑ 
Hematocrit (%) 3% ↓ 8% ↓ 14% ↓ 
Albumin 5% ↓ 16% ↓ 31% ↓ 
α1-acid glycoprotein 1% ↓ 22% ↓ 19% ↓ 
Glomerular filtration rate 
(mL/min) 
19% ↑ 37% ↑ 40% ↑ 
Effective renal plasma flow (L/h) 38% ↑ 48% ↑ 31% ↑ 
Creatinine clearance (mL/min) 28% ↑ 58% ↑ 26% ↑ 
Uterine blood flow (L/h) 923% ↑ 1567% ↑ 2771% ↑ 
Hepatic blood flow (L/h) ↔ ↔ ↔ 
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1.3. Dexmedetomidine 
Dexmedetomidine (DEX; Precedex®), approved by Food and Drug Administration (FDA) 
in 1999 for the use as a sedative in intensive care unit (ICU), is a potent and highly 
selective α2-adrenoceptor agonist. Its affinity for binding to the α2: α1 receptor is 1600:1 
compared with 200:1 for clonidine (most commonly used α2 agonist by 
anesthesiologists). DEX has significant sedative, analgesic and anxiolytic effects without 
causing respiratory depression. In comparison to most of the clinically used anesthetic 
agents, DEX offers a sedative-hypnotic as well as analgesic effect (Farag E et al., 2012). 
Its major side effects include hypotension and bradycardia. In recent years, DEX has 
become one of the effective therapeutic drugs with substantial merits in the perioperative 
use for a wide range of anesthetic management (Arcangeli A et al., 2009). It can be used 
either as the sole sedative or as an adjunct to general anesthesia. Its favorable 
pharmacodynamics and clinical effects are due to its distinguished mechanism of actions 
(Gertler R et al., 2001). 
1.3.1. Physicochemical properties 
The molecular weight of Precedex (DEX hydrochloride) is 236.7 Da and the structural 
formula is shown in Figure 1. Its logP at pH 7.4 is 2.89 and the pKa = 7.1. It is a white 
powder and is soluble in water (Precedex injection label). Each vial contains 236 μg of 
DEX hydrochloride equivalent to 200 μg of DEX in 2 mL to make the concentration equal 
to 100 μg/mL (Figure 1). 
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                         Dexmedetomidine                     Precedex® (DEX hydrochloride injection) 
Figure 1 Chemical structures of dexmedetomidine and FDA-approved Precedex® 
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1.3.2. Pharmacology 
1.3.2.1 Mechanism of action 
The mechanism of action of DEX is different from those of currently used sedatives, 
including clonidine. Physiologic responses mediated by the stimulation of the receptors 
vary by locations (Figure 2) (Kamibayashi T et al., 2000; Gertler R et al., 2001). The 
pharmacological effects of α2-adrenoceptor agonists that act on pre- and post-synaptic 
adrenoceptors are quite complex. Normally, norepinephrine release that terminates 
propagation of pain signals is hindered by the activation of presynaptic α2-adrenoceptors 
(Figure 3), while the inhibition of sympathetic activity by postsynaptic activation in the 
CNS leads to hypotension and bradycardia (Gertler R et al., 2001). Therefore, DEX 
combines these actions and produces the effects of sedation, analgesia and anxiolysis.  
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Figure 2 Responses mediated by α2-adrenoceptors (Kamibayashi T et al., 2000) 
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Figure 3 Physiology of α2-adrenoceptor agonists receptor (Gertler R et al., 2001) 
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1.3.2.2 CNS effects 
DEX has activity at various locations in the CNS. The sedative effects produced by DEX 
primarily depend on the activation of G-protein binding receptors in the locus coeruleus 
of the brain stem, rather than the activation of the γ-aminobutyric acid (GABA) receptor 
that is caused by traditional sedatives like propofol and benzodiazepines (midazolam). 
Sedation and analgesia as well as hypotension and bradycardia that are caused by the 
inhibition of neuronal firing are associated with the stimulation of α2-adrenoceptors in the 
brain and spinal cord. 
The neuroprotective properties of DEX have been demonstrated in neonatal rats to 
attenuate anesthetic-induced neurotoxicity (Sanders RD et al., 2009; Sanders RD et al., 
2010). Experimental data have suggested that the neuroprotective effect of DEX might 
involve other signaling pathways in the brain in addition to α2-adrenoceptor agonism. 
Observations have also revealed the clinical benefits of these brain protective effects as 
DEX shortens the period of coma or delirium in patients in the ICU. Therefore, DEX may 
be a desirable anesthetic agent for pregnant mothers by providing adequate sedation 
with the added benefit of neuroprotection on fetuses (Afonso J et al., 2012). 
1.3.2.3 Cardiovascular effects 
A biphasic, dose-dependent cardiovascular response has been described after DEX 
administration (Dyck JB et al., 1993; Hall JE et al., 2000; Gertler R et al., 2001). At low 
doses, through the activation in both peripheral and central systems, DEX exerts several 
pharmacological actions such as modest decrease in heart rate and a slight reduction in 
blood pressure (Khan ZP et al., 1999). Stable hemodynamic response is expected when 
DEX is administered as a continuous infusion. Severe hypotension usually occurs in 
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patients with hypovolemia. High doses of DEX could cause hypertension mainly due to 
its activation of α2B-adrenoceptors located in vascular smooth muscles.  
1.3.2.4 Respiratory effects 
In general, α2-adrenoceptor agonists have minimal effects on ventilation. DEX could 
provide sedative, analgesic, and anxiolytic effects, as well as respiratory stability without 
causing ventilator depression. The lack of respiratory depression with DEX makes it 
attractive for use in the pregnant woman as avoiding respiratory depression prevents the 
development of apnea which may easily occur in the sedated pregnant woman (Bucklin 
A et al., 2012). In in vivo studies, α2 stimulation is also indicated to cause airway smooth 
muscle relaxation, thereby preventing bronchoconstriction. 
1.3.2.5 Renal system effects 
The diuresis and natriuresis owing to the reduced efferent sympathetic outflow of the 
renal nerve are caused by the activation of α2-adrenoreceptors in kidney. A study has 
demonstrated that low DEX doses could inhibit the vasopressin secretion, causing 
aqueous diuresis in anesthetized dogs. By these actions it is suggested that DEX plays 
a potential role in protecting kidneys against ischemic events (Villela NR et al., 2005).   
1.3.2.6 Endocrine effects 
Generally, α2-adrenoreceptor agonists affect the endocrine system through their effects 
on sympathetic outflow and the decrease of catecholamines. This can inhibit the 
secretions of cortisol and adrenocorticotropic hormone attenuating the responses to 
stress (Venn RM et al., 2001). Stimulation of α2-adrenoreceptors by agonists could also 
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temporarily result in direct inhibition of insulin release in Langerhans cells along with 
detectable clinical hyperglycemia (Angel I et al., 1988). 
1.3.3. Clinical pharmacokinetics and pharmacodynamics  
1.3.3.1 Dosage 
The dosage for adult ICU sedation is usually started with a loading infusion of 1 μg/kg for 
10 min, then a maintenance infusion (< 24 h), at 0.2-0.7 μg/kg/h. The usual dosage for 
non-ICU adult procedural sedation is started with an initial infusion of 1 μg/kg over 10 
min, followed by a maintenance infusion initiated at 0.6 μg/kg/h and titrated with doses in 
the range of 0.2-1 μg/kg/h to achieve the desired clinical effect (Precedex injection 
label).  
1.3.3.2 Pharmacokinetics 
Following IV administration of DEX at the clinical dose range of 0.2-0.7 μg/kg/h up to 24 
h, linear PK has been observed. It has been reported that DEX could be rapidly 
distributed to the body with a distributional half-life (t1/2) of 6 min. The terminal elimination 
half-life (t1/2) is approximately 2 h. Volume of distribution (Vss) and clearance (CL) are 
approximately 118 L and 39 L/h, respectively (for a body weight of 72 kg). Table 2 
provides a comparison of DEX pharmacokinetics with those of other commonly used 
sedatives (Short J, 2010). Therefore, DEX has been suggested to have a very rapid 
onset of action and be suitable for short-term sedation due to both its relatively rapid 
distribution and short elimination. Moreover, the dosage of DEX can be easily adjustable 
by titration to achieve the desired clinical effect.  
The plasma protein binding of DEX in males and females is similar (93.7%) and 
consistent over the different plasma concentrations tested. There is no significant 
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difference in protein binding between groups with normal and impaired renal function. In 
contrast, plasma protein bound DEX is significantly decreased in hepatic impaired 
subjects compared to healthy subjects. 
DEX undergoes both direct glucuronidation (major metabolic pathway) and cytochrome 
P450 (CYP) mediated oxidation, largely mediated by CYP2A6. In a mass balance study, 
95% and 4% of DEX radioactive metabolites were recovered in urine and feces, 
respectively, following IV administration of radiolabeled DEX. In contrast, only a small 
amount of unchanged DEX was excreted through the urine and feces. The result 
indicated that the N-glucuronide metabolite of DEX accounts for 34% of DEX excreted in 
the urine. (Precedex injection label).  
1.3.3.3 Pharmacodynamics 
Clinical effects of DEX compared with other commonly used sedatives are summarized 
in Table 3 (Short J, 2010). Unlike the other commonly used sedatives, DEX offers a 
variety of favorable pharmacodynamic properties, such as arousability promotion during 
sedation, stress response control, shivering reduction, etc. Therefore, combining all 
these effects, DEX can be used as a single agent to produce adequate and cooperative 
sedation avoiding the side effects of multi-agent treatments.  
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Table 2 Pharmacokinetics of DEX vs. other commonly used sedatives (Short J, 
2010) 
 
 
 
 
 
 
 
 
 
 
 
Agent 
Elimination 
Half-life, h 
Systemic Clearance, 
mL/kg/min 
Potential Effects for 
Accumulation 
Dexmedetomidine 2 0.32-0.64 mL/kg/h Hepatic insufficiency 
Clonidine 6-23 1.9-4.3 Renal insufficiency 
Diazepam 21-120 0.4-0.9 Hepatic/renal insufficiency 
Midazolam 3.4-11 4.3-6.6 Hepatic/renal insufficiency 
Lorazepam 10-15 1.2-4.1 Hepatic insufficiency 
Propofol 6.3-32 17-31 None 
Morphine 2.0-5.5 8.6-23 Hepatic/renal insufficiency 
Fentanyl 6.9-36.0 8.6-15 Hepatic impairment 
Haloperidol 28-38 10-13 Hepatic insufficiency 
 
0.005-0.011 
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Table 3 Clinical effects of DEX vs. other commonly used sedatives (Short J, 2010) 
 
Effects Dexmedetomdine Benzodiazepines Propofol Opioids Haloperidol 
Sedation X X X X X 
Alleviation of anxiety X X    
Analgesic properties X   X  
Promotion of arousability during 
sedation 
X     
Facilitation of ventilation during 
weaning 
X     
No respiratory depression X    X 
Control of delirium X    X 
Organ protection X  X   
Control of stress response X     
Reduction of shivering X     
Cooperative sedation X     
Mimicking of natural sleep X     
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1.3.4. Toxicity/Adverse effects 
DEX exerts several adverse effects such as hypotension, bradycardia, hypertension, 
nausea, atrial fibrillation and hypoxia. A short period of rapidly increased blood pressure 
and heart rate fall occur following DEX administration due to the initial loading dose of 1 
μg/kg. Slow infusion of DEX can attenuate the initial hypertension that results from the 
stimulation of α2B-adrenoceptor in vascular smooth muscle. The change in elevated 
mean arterial pressure for the first 10 min is within the range of 7%, and the heart rate is 
reduced by 16-18% (Hall JE et al., 2000). After the first 10 min, slight hypotension is 
usually observed due to the inhibition of the central sympathetic outflow. Additionally, 
stimulation of the presynaptic α2-adrenoceptors decreases the release of norepinephrine 
causing hypotension and bradycardia. In the postoperative period, these similar effects 
might also be seen. But for patients with hypovolemia, those effects could be very 
harmful (Precedex injection label). The instances of respiratory depression caused by 
DEX have been less compared to other sedatives. 
1.3.5. Usage during pregnancy  
Research on the use of DEX during pregnancy is still limited and its impact on the 
developing fetus associated with the adverse effects is yet unclear. Several studies have 
indicated that DEX crosses the placenta, but its safety has not been established in 
pregnancy. In an in vitro human placenta study, approximately 23.9% of DEX transferred 
from the maternal to the fetal side of the placenta (Ala-Kokko TI et al., 1997). In an in 
vivo pregnant rat study, transfer of DEX from mother to fetus is observed when 
radiolabeled DEX is administered subcutaneously. To date there are no reports of 
teratogenic effects in rats after subcutaneous administration and in rabbits after IV 
administration during fetal development. However, lower rat offspring weights were 
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observed in another reproductive toxicity study (Precedex injection label). In a case 
report on the use of DEX during pregnancy close to term, human placental transfer of 
DEX has been demonstrated by measuring the drug concentrations in the neonate, but 
no information is available on its PK or PD during pregnancy (Neumann MM et al., 
2009). There have been no adequate and well-controlled studies of DEX use in pregnant 
women. The FDA has classified DEX as a Pregnancy Category C drug which indicates 
that this drug is recommended for use during pregnancy only if the potential benefits 
justify the potential risk to the fetus (Table 4).  
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Table 4 United States FDA pharmaceutical pregnancy categories (Wikipedia Pregnancy category http://en.wikipedia.org/) 
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1.4. Placental transfer and metabolism 
1.4.1. Placentation 
Mammalian placentas can be classified by their macroscopic appearance, as being 
diffuse, cotyledonary, zonary, and discoid (Figure 4A). Another conventional way of 
classification is according to the Grosser classification based on the number of layers 
between maternal and fetal blood: (1) hemochorial (human and rat); (2) 
endotheliochorial (cat and dog); and (3) epitheliochorial (sheep, pig and horse), as 
shown in Figure 4B. The structural differences in placentas among different species 
affect their functions, as summarized below (Rurak DW, 2001; Syme MR et al., 2004; 
Włoch S et al., 2009; Furukawa S et al., 2014).  
Hemochorial placenta: Maternal blood in the hemochorial placenta is in direct contact 
with trophoblast layers. According to the number of trophoblast layers between maternal 
blood and fetal endothelium, hemochorial placentas are further divided into three 
subgroups. The hemochorial placenta exhibits the greatest destruction, with the uterine 
epithelium underlying basement membrane and maternal endothelium all being lost. 
Endotheliochorial placenta: The endotheliochorial placenta lacks the uterine epithelium, 
which is destroyed during placentation; thus, on both sides of the placenta the capillary 
endothelium is in contact with the trophoblast. 
Epitheliochorial placenta: Placentas with endometrial epithelium and uterine endothelium 
are classified as epitheliochorial. In epitheliochorial placenta, no uterine cell layers are 
destroyed. Thus there are six layers that separate maternal from fetal blood and the 
uterine epithelium is in contact with the trophoblast layer of the conceptus. 
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Figure 4 Placentation classifications by (A) appearance and (B) layers (Rurak 
DW, 2001) 
 
(i) hemochorial, (ii) endotheliochorial, and (iii) epitheliochorial.  
 
MB: maternal blood, ME: maternal endothelium, MCT: maternal connective tissue, 
S: syncytiotrophoblast, UE: uterine epithelium, CE: chorionic epithelium, FCT: 
fetal connective tissue, FE: fetal endothelium, and FB: fetal blood. 
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1.4.2. Placental transfer 
The role of placenta involves supplying the fetus with oxygen, nutrients, cytokines, 
growth factors, and hormones, as well as eliminating toxic metabolites, but also acting 
as a protective barrier for xenobiotics. There are several ways of placental exchange 
including passive diffusion, facilitated diffusion, active transport, phagocytosis and 
pinocytosis (Reynolds F et al., 1989; Syme MR et al., 2004; Włoch S et al., 2009). 
1.4.2.1 Passive diffusion 
Passive transport appears to be the primary way of substrate exchange in the placenta, 
using the differences in the concentration gradient between the maternal and fetal blood 
to drive the flux. During pregnancy, most of the drugs that are administered to the 
maternal circulation will enter the fetal circulation via passive diffusion to varying extents. 
This process does not involve energy consumption, nor is it subject to saturation or 
competitive inhibition.   
Passive diffusion can be described by Fick’s Law: 
𝑉𝑑𝑖𝑓𝑓 =  
𝐷 × 𝑆 × (𝐶𝑀 −  𝐶𝐹)
𝑎
 
Where Vdiff is diffusion rate, D is the coefficient of diffusion, S is the exchange surface 
area, CM is the maternal concentration, CF is the fetal concentration and 𝑎 represents 
the thickness of placenta. 
According to the above equation, the amount of substrates that can cross a membrane 
depends on the concentration difference between two sides of the membrane, and 
26 
 
surface area and thickness of membrane. With the advancement of gestational age, the 
placental surface area increased and placental thickness decreased, and that leads to 
the increased amount of nutrition and energy across the placenta for fetal development. 
The trend is the same for the drugs across the placenta by passive diffusion.  
The physicochemical properties of drugs that determine the placental transfer through 
passive diffusion are molecular weight, pKa, lipid solubility and protein binding. Highly 
lipid-soluble drugs with low-molecular weight (< 500 Da) that are predominantly non-
ionized are easily transferred across placenta, and only the free fraction of drugs can 
cross the placenta.  
1.4.2.2 Facilitated diffusion 
Facilitated diffusion is a process of spontaneous passive transport across placenta via 
specific transmembrane proteins. This is process can become saturated at high 
concentrations, but does not require energy input. Unlike the passive diffusion which 
does not undergo saturation, the rate of the facilitated diffusion is saturable with respect 
to the concentration difference between maternal and fetal circulations. It is a suitable 
mechanism for nutrients such as glucose, which is in plentiful supply in the maternal 
circulation. To date, only a few drugs have been suggested as being transported across 
the placenta by the facilitated diffusion mechanism. 
1.4.2.3 Active transport 
Unlike passive and facilitated diffusion, active transport across the placenta requires 
energy consumption that is usually provided by ATP hydrolysis or energy stored in the 
transmembrane electrochemical gradients. Active transporters are located in the apical 
membrane facing the maternal blood space or basal membrane facing the fetal 
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capillaries, where they transfer compounds in and out of synctiotrophoblasts. In addition, 
some transporter proteins are expressed on the capillary endothelium. All active 
transporters can transport drugs against concentration gradients and undergo saturation 
with time. The transport systems are involved with nutrients and drugs whose structure 
are similar to those of endogenous substrates. These active transporters include P-
glycoprotein (P-gp), multidrug resistance proteins (MRPs), breast cancer resistant 
protein (BCRP), monoamine transporters (SERT, NET, OCT3), and organic cation 
transporters (Eshkoli T et al., 2011). 
1.4.2.4 Phagocytosis and pinocytosis 
Drugs can also cross placenta via phagocytosis and pinocytosis. But these processes of 
transfer mechanisms are considered too time-consuming to have any notable impact on 
fetal exposure. 
1.4.3. Placental metabolism 
The placenta acts as a metabolic barrier to foreign substances; however, it plays a 
relatively minor role in drug metabolism compared to hepatic metabolism. Therefore, 
placental metabolism is not considered as a limiting step in the transfer of xenobiotics 
across the placenta. Moreover, in some cases, xenobiotics can become toxic to the fetus 
upon activation by placental enzymes. The expression and activity of phase I enzymes 
(including cytochrome P450s (CYPs)) and phase II enzymes (including UDP-
glucuronosyltransferases (UGTs)) in the human placenta have been well reviewed 
(Syme MR et al., 2004).  
Figure 5 demonstrates the drug disposition in mother and fetus after maternal drug 
administration (Syme MR et al., 2004). Several PK variables including hepatic 
28 
 
metabolism, free drug fraction, as well as transplacental transport and metabolism affect 
drug transfer across the placenta and drug exposure to the fetus. Moreover, these PK 
variables are drug-dependent and vary with fetal and placental development during 
pregnancy. 
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Figure 5 Drug disposition in mother and fetus after drug administration. Black and white arrows indicate parent 
compounds and metabolites, respectively (Syme MR et al., 2004). 
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1.5. Pregnant ewe 
During the past decades our knowledge of human fetal growth and development has 
increased significantly with advanced prenatal diagnosis and care. However, there are 
still many unknowns in complicated cases of human pregnancies. Until today, many 
aspects of human pregnancy cannot be adequately studied, primarily due to both ethical 
and practical challenges and constraints. Alternatively, a variety of animal models have 
been developed and have contributed to our current state of knowledge in both normal 
and complicated pregnancies (Pardi G et al., 2006; Carter AM, 2007).   
While there is no ideal animal model that can truly represent human pregnancy, the 
pregnant ewe has been extensively used to delineate maternal-fetal interactions. This is 
in part due to the distinguished merit of the relatively large size of the fetus that permits 
the implantation of catheters in both maternal and fetal blood vessels for repeated 
sampling from both maternal and fetal sides of the placenta. Figure 6 shows the 
schematic representation of a pregnant ewe model (modified from Barry JS et al., 2008). 
Drug administration/Infusate can be given into either the maternal or the fetal side, and 
blood samples can be collected from maternal and fetal circulations simultaneously. At 
term, fetal lamb is almost the same weight as a human fetus.  
In addition, the relatively large size of the fetal lamb makes fetal surgery easy to handle, 
and the fetus is considered to be more tolerable to the invasive procedures. (Carter AM, 
2003). Therefore, our knowledge of physiology of fetal lamb is more advanced compared 
to that of fetuses of other species. 
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Figure 6 Schematic representation of pregnant ewe model (modified from Barry 
JS et al., 2008) 
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1.6. Placental drug transfer in pregnant ewe 
To date, a variety of drugs have been evaluated using pregnant ewe to understand the 
placental transfer and data extrapolation to humans. These drugs include sedatives 
(Vree TB et al., 1984; Fresno L et al., 2008; Musk GC et al.,2012), opioids (Craft et al., 
1983; Vertommen et al., 1995; Coonen JB et al., 2010), propofol (Andaluz A et al., 
2003), metoclopramide (Riggs KW et al., 1990), ritodrine (Fujimoto S et al., 1984), 
diphenhydramine (Kumar S et al., 1999), and valproic acid (Kumar S et al., 2000). Most 
of the experiments were carried out in chronically instrumented pregnant ewe at 120 
days to near term of gestation after intravenous administration for maternal-fetal PK 
studies with or without the evaluation of drug effects in the fetus. Generally, the extent of 
placental transfer is described by fetal/maternal ratio of AUC or fetal/maternal 
concentration ratio at steady state. A compartmental PK model is helpful to describe the 
inter-compartmental relationship between fetus and mother, and to evaluate factors that 
potentially affect the fetal drug exposure. However, non-compartmental PK analysis of 
total drug concentrations was primarily performed for the studies in pregnant ewe.  
Musk GC et al. have demonstrated that medetomidine and ketamine can rapidly cross 
the pregnant ewe placenta. Although blood samples were obtained only at three time 
points, comparable maternal and fetal concentrations were observed (Musk GC et al., 
2012). Fresno L et al. have reported that etomidate, an anesthetic agent, also has the 
ability to transfer across the placenta of pregnant ewe. The fetal/maternal AUC ratio is 
0.4, and maternal and fetal elimination rates are similar (Fresno L et al., 2008). 
Diphenhydramine has also exhibited similar elimination rates in pregnant ewe and fetus, 
but the fetal/maternal AUC ratio is very high (0.85) (Yoo SD et al., 1986). In another 
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study of propofol in pregnant ewe, it has been demonstrated that the fetal exposure was 
approximately 19% of maternal exposure. The elimination rate in fetus was 
comparatively slower than that in pregnant ewe (Andaluz A et al., 2003). These 
differences are due to drug specific variations in physicochemical and pharmacokinetic 
characteristics.   
Other authors have suggested that although plasma drug concentrations were detected 
in fetus, maternal administration of remifentanil (Coonen JB et al., 2010) did not result in 
significant fetal hemodynamic changes, nor ritodrine (Fujimoto S et al., 1984) for 
cardiovascular changes. Similarly, high amount of tritiated digoxin in fetus and amniotic 
fluid did not have significant adverse effects (Hernandez A et al., 1975).  
A few placental transfer studies using a two-compartmental PK model were reported. 
Kumar et al. have found that the maternal plasma concentration of diphenhydramine 
was affected by maternal plasma protein binding and non-placental clearance; whereas 
the concentration in the fetus was determined by the first-pass hepatic drug uptake. The 
unbound fraction of diphenhydramine in pregnant ewe (12%) at steady state was less 
than that in the fetus (30%) (Kumar S et al., 1999). The placental transfer of 
metoclopramide was also investigated to derive the non-placental clearance, and lower 
plasma protein binding in fetus was also observed (Riggs KW et al., 1990). Another 
study has systematically examined the disposition of valproic acid in pregnant ewe, and 
determined the mechanism of valproic acid placental transfer and nonlinear plasma 
protein binding in both pregnant ewe and fetus (Kumar S et al., 2000).  
Recently, Uemura et al. have monitored the cardiovascular effects of DEX using 
pregnant ewe at 92 days of gestation, where significant fetal response was not detected. 
However, the drug concentrations were not reported (Uemura K et al., 2012). 
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Summary 
This survey of the literature reveals that DEX has been suggested to be suitable for 
maternal-fetal anesthesia due to its distinguished clinical merits with the added benefit of 
neuroprotection on fetuses. However, the impact of the use of DEX during pregnancy on 
fetal development that may be associated with hypotension and bradycardia is not fully 
understood. The physiological changes during pregnancy have the potential to alter both 
the pharmacokinetics and pharmacodynamics of DEX. Therefore, investigation of fetal 
exposure and response to the maternal use of DEX during pregnancy will contribute to 
our understanding for the recommendation of DEX usage in pregnancy. Due to the 
ethical issues in performing experiments on fetuses, maternal-fetal PK research in 
humans is limited. Despite the lower permeability of pregnant ewe placenta compared to 
that of humans, the effect should be less pronounced for DEX. The pregnant ewes may 
be a desirable experimental model to study the placental transfer, pharmacokinetic, and 
cardiovascular effects of DEX in both pregnant ewe and fetus.  
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Chapter 2 Objective and Specific Aims 
 
 
2.1. Hypotheses 
Our first hypothesis is that the “maternal use of DEX will have no significant or 
manageable adverse effects on fetuses if the fetal exposure to DEX is limited or 
predictable”. 
Our second hypothesis is that “understanding of the fetal exposure and response to DEX 
after drug administration to maternal circulation will provide a more rational 
recommendation of DEX use during pregnancy based on pharmacokinetic (PK) and 
pharmacodynamic (PD) studies”. 
2.2. Objective 
Our proposed research is focused on the investigation of fetal exposure 
(pharmacokinetics) and response (safety) to the maternal use of DEX during pregnancy. 
In this study, pregnant ewe was selected as an experimental model due to the ethical 
constraints to the acquisition of maternal-fetal information in humans. The overall 
objective of the study is to characterize the maternal-fetal PK and placental transfer of 
DEX, as well as to evaluate the PD (cardiovascular response) in the pregnant ewe and 
fetus. The rationale is that the severity of adverse effects is associated with the extent of 
fetal drug exposure. Factors such as the degree of protein binding and drug metabolism 
in fetuses can play critical roles in drug disposition in pregnant ewe and fetus, and thus 
have a significant impact on the extent of fetal drug exposure. 
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2.3. Specific Aims 
Towards our goal, three major specific aims were proposed: (1) to determine the DEX 
exposure and cardiovascular response in pregnant ewe and fetus, as well as the extent 
of placental transfer, (2) to characterize the differential plasma protein binding and drug 
metabolism in pregnant ewe and fetus, and (3) to establish the models of PK and PD in 
pregnant ewe and fetus. 
2.3.1. To determine the DEX exposure and cardiovascular response in 
pregnant ewe and fetus, as well as the extent of placental transfer 
 To establish a validated LC-MS/MS assay that can be used for the quantification 
of DEX in both pregnant ewes and fetuses 
 To establish plasma concentration-time profiles of DEX in pregnant ewe and 
fetus 
 To evaluate the areas under concentration-time curves in pregnant ewe and 
fetus using non-compartmental PK analysis 
 To evaluate the extent of placental transfer from pregnant ewe to fetus by the 
ratio between fetal and maternal systemic exposures  
 To evaluate the adverse effects (hypotension and bradycardia) on pregnant ewe 
and fetus after maternal administration of DEX  
2.3.2. To characterize the differential plasma protein binding and drug 
metabolism in pregnant ewe and fetus 
 To comparatively evaluate plasma protein binding of DEX between pregnant ewe 
and fetus in blank plasma, and in PK plasma samples from DEX-treated ewes. 
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 To identify the UGT microsomal metabolism of DEX in placenta, as well as in 
maternal and fetal livers 
 To determine the differential UGT activities in hepatic microsomes between 
pregnant ewe and fetus.  
2.3.3. To establish the models of PK and PD in pregnant ewe and fetus 
 To develop a PK model that can best describe the maternal and fetal DEX data 
in pregnant ewe and fetus 
 To develop a PD model that can best describe the maternal and fetal 
cardiovascular response to DEX in pregnant ewe and fetus 
 To evaluate the PK/PD relationship in pregnant ewe 
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Chapter 3 Materials and Methods 
 
 
3.1. Materials 
3.1.1. Chemicals and Materials 
 Dexmedetomidine (DEX) hydrochloride powder purchased from Fisher Scientific 
(Pittsburgh, PA, USA) was used for LC-MS/MS assay development and 
validation. 
 Testosterone purchased from Indofine Chemical Co., Inc (Hillsborough, NJ, USA) 
was used as internal standard (IS) for LC-MS/MS analysis of DEX. 
 Acetonitrile (ACN) HPLC-grade (EMD, Gibbstown, NJ, USA) was used for 
preparing mobile phase for LC-MS/MS analysis. 
 Methanol HPLC-grade (EMD, Gibbstown, NJ, USA) was used to prepare 
washing solution for LC-MS/MS assays and as a solvent of DEX stock solution.  
 Ethyl acetate (EMD, Gibbstown, NJ, USA) was used as the organic solvent in the 
liquid-liquid extraction of DEX from samples of different biomatrices for LC-
MS/MS analysis. 
 Formic acid   (~ 98%) (Sigma-Aldrich Co., St. Louis, MO, USA) was used as an 
acidic solution to adjust the pH value of mobile phase.  
 Double distilled water was produced by a MiliporeMilli-Q system (Billerica, MA, 
USA). 
 Phosphate-buffered saline (PBS), containing 140 mM NaCl (Sigma Chemical Co., 
St. Louis, MO, USA), 0.4 mM KH2PO4 (Sigma Chemicals Co., St. Louis, MO, 
USA), and 2 mM K2HPO4 (Fisher Scientific Co., Fair Lawn, NJ, USA), was used 
for plasma protein binding assessments. 
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 Drug-free blank plasma samples of pregnant ewe and fetus provided by the 
Texas Children’s Hospital Baylor College of Medicine, Houston, TX, USA, were 
used to prepare the calibration curves for LC-MS/MS assay development, for in 
vitro plasma protein binding assessment, and analysis of pharmacokinetic 
samples of in vivo studies.    
 Drug-free blank placenta and liver samples from pregnant ewe and fetus were 
provided as cubes, approximately 2 cm * 2 cm, by Texas Children’s Hospital 
Baylor College of Medicine, Houston, TX, USA, for in vitro metabolism studies. 
 Homogenization buffer containing 50 mM potassium phosphate buffer (pH 7.4), 
250 mM sucrose (Sigma Chemicals Co., St. Louis, MO, USA), 1 mM EDTA 
(Sigma Chemicals Co., St. Louis, MO, USA), was used in the preparation of liver 
and placenta microsomes. 
 Sodium chloride (Sigma Chemical Co., St. Louis, MO, USA) was dissolved in 
double distilled water to prepare normal saline solution. 
 Genistein was purchased from Indofine Chemicals (Somerville, NJ, USA), and 
used as a typical UGT substrate for in vitro metabolism studies. 
 Pooled human liver microsomes were purchased from BD Biosciences (Woburn, 
MA, USA) for in vitro metabolism studies. 
 BCA protein assay kit (Thermo Scientific Pierce, Rockford, IL, USA) with bovine 
serum albumin as the standard for protein concentration determination. 
 Magnesium chloride (Sigma Chemical Co., St. Louis, MO, USA) for UGT 
microsomal metabolism.  
 Uridine diphosphoglucuronic acid (UDPGA) (Sigma Chemical Co., St. Louis, MO, 
USA) was used for UGT microsomal metabolism. 
 Alamethicin (Sigma Chemical Co., St. Louis, MO, USA) was used as a surfactant 
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in microsomal metabolism incubation 
 Saccharolactone was purchased from Sigma-Aldrich Chemical Co. (St. Louis, 
MO, USA) to drive the UGT metabolism reaction forward to completion.  
3.1.2. Supplies 
 Pipette tips (disposable, white: 1-10 µL, yellow: 10-100 µL and blue: 100-1000 µL, 
VWR, West Chester, PA, USA) were used along with appropriate pipettes (VWR, 
West Chester, PA, USA) for measuring and delivering liquid samples for all 
experiments. 
 Glass pipettes (10 and 20 mL, Drummond Scientific Co., Broomall, PA, USA) 
were used for transferring solutions 
 Polyethylene microcentrifuge tubes (1.5 ml, Axygen Scientific Inc., Union City, 
CA, USA) were used for storing samples from different experiments.  
 Disposable vials (250 µL) were used for preparation of samples for LC-MS/MS 
injections.  
 Flat bottom, clear glass bottles (500, 1000 and 2000 ml; VWR, West Chester, PA, 
USA) were used to store mobile phase and buffers.  
 YM-30 Centrifree® ultrafiltration devices (Millipore Ireland Ltd., Tullagreen, 
Carrigtwohill, Co. Cork, Ireland) were used to separate free from bound DEX in 
plasma protein binding studies. 
 Alcohol wipes (Webcol® Alcohol Preps, Kendall Healthcare Products Co., 
Mansfield, MA, USA) were used to disinfect tissue dissection equipment for 
microsome studies.  
 Cylindrical homogenization glass tubes (Wheaton, Millville, NJ, USA) for 
microsomal preparation.  
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 Polycarbonate centrifuge tubes (Beckman Coulter, Palo Alto, CA, USA) for 
microsomal preparation. 
 96-well plates (BD Biosciences, Woburn, MA, USA) for protein assay  
 Membrane filters (47mm, 0.45 µm, hydrophilic polypropylene; Pall Corp., Ann 
Arbor, MI, USA) were used to filter the mobile phase prior to LC-MS/MS assays. 
 Gloves (lightly powdered, Latex) were used in handling chemicals and samples 
for all experiments. 
3.1.3. Animals 
Following approval by the Institutional Animal Care and Use Committee of Baylor 
College of Medicine, eight third-trimester pregnant Western Cross ewes (Edmiston 
Farms, West Texas, TX, USA) at 132-134 days of gestation (term approximately 147 
days) were studied. Ewes were allowed to acclimatize to the environment for one week 
prior to initiating the studies. Four of the eight ewes had twin pregnancies. 
3.1.4. Equipment, Apparatuses and Software 
 Electronic balance, sensitivity of 0.0001 g (Mettler AE100, Mettler Instrument 
Corp., Hightstown, NJ, USA) was used for all weighing purposes.  
 Centrifuge (Marathon 13K/M, B Hermle AG, Germany) was used for sample 
preparations.  
 Vortex mixer (Vortex-2 Genie, Scientific Industries, Bohemia, NY, USA) was 
used for sample mixing.  
 Columns: Agilent ZORBAX SB-CN column (5.0 μm, 150 *2.1 mm I.D.) was used 
for all HPLC analysis.  Waters BEH C18 (1.7 μm, 2.1×50 mm I.D.) was used for 
all UPLC analysis. 
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 HPLC-MS/MS system consisted of:  
o LC system: Agilent Technologies 1200 series HPLC system (Agilent 
Technologies, Inc., Foster City, CA, USA) 
o MS system: 3200 QTRAP triple quadruple mass spectrometer equipped 
with a TurboIonSpray ion source (Applied Biosystems/MDS SCIEX, 
Foster City, CA, USA). The MS/MS was used to develop and validate the 
method for quantification of DEX in both pregnant ewe and fetus plasma 
samples. 5500 QTRAP mass spectrometer equipped with a 
TurboIonSpray ion source (Applied Biosystems/MDS SCIEX, Foster City, 
CA, USA) was also used to achieve a lower LLOQ.  
o The Analyst Software version 1.5 was used to analyze the data.  
 Waters ACQUITY UPLC system with photodiode array detector and Empower 
software was employed to analyze the parent compounds and the corresponding 
glucuronides.  
 pH-meter (Corning Scholar 425, Corning, NY, USA) was routinely used to 
measure the pH of the mobile phase and to confirm the pH of buffer solutions.  
 Dissection equipment set (Miltex ®, Thomas Scientific, Swedesboro, NJ, USA) 
was used for dissection of liver and placenta tissues. 
 Shaking water bath (model YB-521, American Scientific Products, Japan) was 
used for in vitro metabolism studies.  
 Biotek plate reader (Biotek, Winooski, VT, USA) was used to measure protein 
concentrations. 
 Pipettes (1-10 μL, 10-100 μL, 20-200 μL and 100-1000 μL, Eppendorf, 
Brinkmann Instrument, Inc., Westbury, NY, USA) were used with different sizes 
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of pipette tips to measure and transfer liquid samples.  
 Pipette-aid (Drummond Scientific, Broomall, PA, USA) was attached to glass 
pipettes (10 and 20 mL) and used to transfer liquids.  
 PKSolver, an add-in program in Microsoft Excel was used for non-compartmental 
pharmacokinetic data analysis. 
 Phoenix WinNonlin version 1.3 (Pharsight Corp., Mountainview, CA, USA) was 
used for pharmacokinetic data analysis and pharmacokinetic model development. 
The Phoenix NLME (non-linear mixed effect) package is capable of analyzing 
data with sparse samples, deviated sampling time and/or missing samples.  
 Graphpad Prism version 5.02 (GraphPad Software, San Diego, CA) was used for 
Student's t test, and one-way ANOVA with Tukey’s post hoc test.  
 SigmaPlot 13.0 (Systat Software, San Jose, CA) was used for kinetic analysis in 
the microsome study 
3.2. Methods 
3.2.1. LC-MS/MS assay development for quantifications of DEX in pregnant 
ewe and fetus plasma samples 
3.2.1.1 Rationale 
In order to investigate the DEX usage during pregnancy and maternal-fetal 
pharmacokinetic of DEX in the pregnant ewe model, we have developed a sufficiently 
sensitive, specific, accurate and reliable assay for the determination of DEX in both 
pregnant ewe and fetus plasma samples, as a prerequisite for pharmacokinetic 
characterization of DEX in the pregnant ewe model. This assay could also be employed 
in quantifying DEX in urine and amniotic fluid samples for the pregnant ewe model with 
the same assay protocol. To our knowledge, there are no published HPLC or LC-MS/MS 
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assay readily available to quantify DEX in these biometric samples for pregnant ewe and 
fetus. Methods for the quantification of DEX in rats and humans have been reported. 
However, these methods may not be suitable for the determination of DEX in the ewe as 
the performance of LC-MS/MS methods can vary significantly among species due to the 
matrix effects of different biometrics (Taylor PJ, 2005; Van Eeckhaut A et al., 2009; 
Trufelli H et al., 2011). Analytical bias between species due to different phospholipid 
profiles among human, rodent and non-rodent species has been reported (Gray NP et 
al., 2012). Matrix components present in biological samples can suppress or enhance 
the response of the analyte of interest, which may affect the assay sensitivity and/or 
accuracy. Therefore, we have developed and validated a new HPLC-MS/MS assay 
which enables quantification of DEX concentrations in plasma, urine and amniotic fluid 
for the pregnant ewe model with a single assay protocol. This assay can be easily 
modified to quantify DEX in liver and placental microsomal samples. 
3.2.1.2 Chromatographic conditions 
An Agilent 1200 series HPLC system (Foster City, CA, USA) was used for 
chromatographic analysis. DEX and testosterone (IS) were resolved on an Agilent 
ZORBAX SB-CN column (5.0 µm, 150 mm*2.1 mm I.D.). The mobile phases consisted 
of water (mobile phase A) and 0.5% formic acid in acetonitrile (mobile phase B). A 
gradient elution was started with 5% of mobile phase B, maintaining for 1 min and with a 
linear increment to 100% of mobile phase B from 1 to 3.5 min. The elution was kept 
constant at 100% of mobile phase B for 1.5 min, and then decreased to 5% of mobile 
phase B in 0.5 min. This composition was maintained at 5% of mobile phase B for 2.5 
min. The total running time was 8.0 min. The flow rate was delivered at 0.5 mL/min, and 
the injection volume was 50 µL. 
  
45 
 
3.2.1.3 Mass spectrometry conditions 
The column effluent was monitored using an HPLC-MS/MS of 3200 QTRAP® with a 
TurboIonSpray ion source. The IonSpray heater was set at 500°C. Curtain gas, nebulizer 
gas and heater gas were at 10, 20 and 60 psi, respectively. IonSpray needle voltage was 
set at 5,500 V, and the collision activated dissociation gas was set to medium. 
Transition ions from a specific precursor ion to product ion [M+H]+ were detected by 
using optimal multiple reaction monitoring (MRM): m/z 201.5 → 95.4 for DEX and m/z 
289.2 → 109.1 for the IS, respectively. The collision energy was set at 22 and 34 eV for 
DEX and IS, respectively. Other compound parameters were determined using the 
QTRAP instrument and Analyst® Software. Finally, the positive ion electrospray MS/MS 
product ion spectra of DEX and IS were established in Figure 7. Formic acid of 0.1, 0.3 
and 0.5% in mobile phase B were tested, and 0.5% was selected as it resulted in the 
sharpest and symmetrical peak shape, with no significant suppression issue in positive 
ion mode.  
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(a) DEX 
 
(b) IS 
 
Figure 7 MRM product ions mass spectra for (a) DEX and (b) internal standard. 
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3.2.1.4 Preparation of calibration standards and quality control (QC) samples 
Stock solutions of DEX and IS were prepared at concentrations of 1.0 mg/mL in 
methanol and 100 µM in acetonitrile, respectively. Stock solutions were stored at - 20°C 
until use for the preparation of working solutions. A series of DEX standard working 
solutions were freshly prepared by adding appropriate volumes of DEX stock solution 
(1.0 mg/mL) with 30% aqueous acetonitrile to obtain the DEX concentrations of 0.25, 
0.50, 1, 2.5, 5, 10, 25 and 50 ng/mL, respectively. These standard working solutions of 
DEX (20 µL) were spiked to blank ewe samples (180 µL) to yield calibration standards of 
25, 50, 100, 250, 500, 1000, 2500 and 5000 pg/mL in plasma. Three levels of QC 
samples of 50, 500 and 2500 pg/mL were prepared in the same manner. 
3.2.1.5 Preparation of plasma samples 
Standards and QC samples were extracted by liquid-liquid extraction. An aliquot (200 
µL) of plasma samples was extracted with 1 mL of ethyl acetate after the addition of 20 
µL of freshly prepared IS stock dilution (0.5 µM testosterone in 30% acetonitrile). The 
mixture was then vortexed for 1.5 min.  After centrifugation of the mixture at 14,800 rpm 
for 20 min, the upper organic layer was transferred to eppendorf vials and evaporated to 
dryness by air. The residue was reconstituted with 200 µl of 30% acetonitrile in water 
followed by centrifugation at 14,800 rpm for 20 min. A volume of 50 µL of the 
supernatant was injected into HPLC-MS/MS for the DEX quantification. 
3.2.1.6 Method validation 
Method validation was performed for sensitivity, specificity, accuracy, precision, recovery, 
and stability, according to the “Guidance for Industry -Bioanalytical Method Validation" 
document from the United States Food and Drug Administration (FDA) (FDA Guidance 
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for Industry, 2001). Each analytical run included samples of a double blank (without IS), 
a blank (with IS) and calibration standards, as well as replicate sets of QC samples. 
3.2.1.6.1 Linearity, sensitivity and specificity 
Linear calibration curves in ewe samples were constructed by plotting the peak area 
ratio of DEX/IS versus DEX concentrations over the range of 25-5000 pg/ml. The 
linearity expressed as y = a + bx was established by using linear regression analysis. 
The LLOQ was determined as the concentration producing a peak with a signal-to-noise 
ratio of 10:1. The noise level was the peak area resulting from the blank sample. Each 
nominal concentration should meet the FDA criteria that deviations should not exceed 
20% at LLOQ and be less than 15% at other calibration standard concentrations. The 
specificity of the HPLC-MS/MS method towards endogenous components in plasma was 
determined by analyzing six different sources of non-pooled and analyte-free matrices 
over the selected concentration range. 
3.2.1.6.2 Accuracy and precision 
QC samples containing low, medium and high DEX concentrations were used to 
evaluate accuracy and precision of the developed assay method. The intra-day assay 
accuracy and precision were determined by analyzing replicates (n=6) of the QC 
samples prepared on the same day, while inter-day assay accuracy and precision were 
determined using replicates of the QC samples conducted on 3 different days. The 
assay accuracy was expressed as a percentage of the nominal concentration, (observed 
concentration/nominal concentration) ×100%, and the precision was expressed by the 
coefficient of variance (CV). 
3.2.1.6.3 Recovery and matrix effect 
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To determine extraction recoveries, three level concentrations of DEX (50, 500, 2500 
pg/ml) were prepared in blank ewe samples and reconstitution solution (30% acetonitrile 
in water), respectively. The extraction recoveries (expressed as a percentage) were 
calculated by comparing the peak area of samples spiked before extraction with those 
spiked after extraction into blank ewe extracts at three different DEX concentration 
levels. 
Matrix effect from endogenous substances present in extracted biological samples may 
cause ion suppression or enhancement of the signal. Matrix effects were assessed by 
comparing the peak areas of DEX after the addition of low, medium and high 
concentrations into reconstitution solution (30% acetonitrile) (A) with those of DEX 
spiked after extraction into blank extracts (B). The studies were performed with six 
different lots of matrices. The peak area ratio of B/A as a percentage was used as a 
quantitative measure of the matrix effect.  
3.2.1.6.4 Stability 
Replicates (n=6) of three levels of QC samples of maternal and fetal plasma, 
respectively, were used to assess the stability of DEX during sample storage and 
preparation procedures. The freeze and thaw stability was assessed after three freeze 
and thaw cycles. The short-term stability was tested after the QC samples were kept at 
room temperature for 3 h. The post-preparative stability was measured by determining 
QC samples prior to and 24 h after storage in the autosampler condition (20°C). Mean (± 
SD) percentage of nominal concentrations was calculated for the above stability tests 
using observed concentration from the stability testing samples in reference to that from 
freshly prepared samples.  
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3.2.2. Pharmacokinetic and pharmacodynamic studies in pregnant ewe and 
fetus 
3.2.2.1 Animal study protocol 
Surgeries and catheterization of the ewes and fetuses were carried out by our 
collaborators at Texas Children’s Hospital, Baylor College of Medicine (Houston, TX, 
USA), using a technique described previously (Olutoye OA et al., 2011). Briefly, the 
third-trimester pregnant ewes received anesthesia with 5% isoflurane in oxygen and 
surgical anesthesia maintained with 2% isoflurane in oxygen following endotracheal 
intubation. The ewes had a peripheral vein and internal jugular vein catheter inserted for 
intravenous fluid and study drug administration, respectively. Ewes received a 
maintenance infusion as well as fluid replacement of 10 mL/kg/h of lactated Ringer’s 
solution for the duration of abdominal exposure. A carotid arterial catheter was inserted 
for invasive blood pressure monitoring and ewes were positioned supine with a left 
lateral tilt to avoid aortocaval compression. A laparotomy was performed with a 
hysterotomy in each gravid uterine horn. The hind limb of each fetus was exposed and 
femoral arterial and venous catheters placed for invasive arterial blood pressure 
monitoring and blood sampling. 
Administration of DEX to the ewe was initiated following instrumentation of the fetuses 
as the hysterotomy incision was being closed. A loading dose of DEX at 1 μg/kg over 10 
min followed by an infusion of 1 μg/kg/h for 1 h was administered as in prior studies. 
Maternal and fetal arterial and venous blood samples were obtained at baseline (0 min), 
after the loading dose (10 min), and at 20, 40, 70 (end of 1 h infusion), 130, 190 and 250 
min (3 h after initiation of the loading dose) for DEX quantification. Maternal (1 ml) and 
fetal (0.5 ml) samples were drawn simultaneously by two investigators. Blood samples 
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were centrifuged, plasma separated aliquotted and stored at -80°C for subsequent LC-
MS/MS analysis. Blank plasma samples collected before drug administration from 
pregnant ewe and fetus were used as the respective baseline for quantifications.  
Maternal and fetal heart rates as well as systolic and diastolic blood pressures were 
monitored continuously (Spacelabs Monitor Ultraview SL, Garnerville, NY, USA). Arterial 
blood gas values were obtained at baseline and 60 min following completion of DEX 
infusion. At the conclusion of this acute, non-survival experimental protocol, all the 
animals were euthanized with intravenous pentobarbital and potassium chloride.  
3.2.2.2 LC-MS/MS assay of plasma samples from pharmacokinetic studies 
Maternal and fetal plasma samples from the pharmacokinetic studies were assayed 
using the LC-MS/MS method in Section 3.2.1 
3.2.2.3 Non-compartmental pharmacokinetic analysis 
Pharmacokinetic analysis of data was performed using non-compartmental method with 
PKSolver, an add-in program in Microsoft Excel (Zhang Y et al., 2010). The maximum 
plasma DEX concentration (Cmax) and the time to reach Cmax (Tmax) were derived from 
the individual plasma concentration profiles. The area under the curve from the time of 
administration to the last quantifiable sample time point (AUCt) was calculated with the 
linear-up/log down trapezoidal rule (Equations 1 and 2) (Gabrielsson J et al., 2012). The 
systemic exposure was calculated from the time of administration to infinity (AUC∞) and 
represents the sum of AUCt plus the area under the extrapolated curve (Equation 3). The 
AUC extrapolated from the last quantifiable time point was calculated as Clast/λ (Equation 
4). The terminal elimination rate constant (λ) was estimated from the terminal three 
datum points of the plasma concentrations (natural logarithmic transformed 
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concentrations) versus time profile, using linear regression. The terminal elimination half-
life (t1/2) was calculated by ln(2)/λ (Equation 5). The maternal systemic clearance (CL) 
was derived by the ratio of the total dose to AUC∞ (Dose/ AUC∞) (Equation 6). The 
volume of distribution (V) was derived by the ratio of CL/λ (Equation 7). 
The two main trapezoidal rules for AUC calculations are linear and log-linear rules. 
Linear rules:  
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3.2.2.4 Placental transfer of DEX from pregnant ewe to fetus 
The ratio between fetal and maternal systemic exposures was calculated to evaluate the 
degree of placental transfer. Maternal and fetal DEX areas under the concentration-time 
curve (AUCs) from 0 to 250 min were derived individually, and the partition coefficient 
from mother to fetus (KFM) was established by the ratio of AUCfetus/AUCmother. The lower 
the KFM, the lower the degree of drug transfer from ewe to fetus. 
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3.2.2.5 Pharmacodynamic analysis 
Blood pressure is measured in millimeters of mercury (mmHg). Systolic pressure is the 
greatest blood pressure on the wall of the arteries when blood is pumping through the 
arteries, whereas diastolic pressure is the resting phase of the blood pumping cycle. In 
practice, mean arterial pressure (MAP) was determined by measurements of the systolic 
blood pressure (SBP) and diastolic blood pressure (DBP) as follows:  
 
 
 
 
3.2.2.6 Statistical analysis 
DEX concentration data, non-compartmental PK parameters and KFM among different 
time points were reported as mean and standard deviation (SD). The statistical 
difference in KFM was examined using one-way ANOVA followed by Tukey’s post hoc 
test at p < 0.05 (Graphpad Prism version 5.02). Blood pressure and heart rate were 
DBPSBPMAP
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analyzed using ANOVA for repeated measures and the student’s t-test was used where 
appropriate. 
3.2.3. Plasma protein binding  
3.2.3.1 Determination of fraction unbound of DEX in pharmacokinetic samples  
Maternal and fetal plasma samples from pharmacokinetic studies in Section 3.2.3 were 
thawed and incubated at 37 °C for 30 min. YM-30 Centrifree® ultrafiltration devices 
(Figure 8) were used to determine the unbound fraction (fu) of DEX for each sample. 
Two hundred μL aliquots of the plasma samples were added into the sample reservoir of 
the ultrafiltration units, and then the units were centrifuged with a swinging-bucket rotor 
at 1,000 g (37 °C) for 30 min. Fifty μL ultrafiltrate from the filtrate cup was transferred for 
sample preparation and analysis.  
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Figure 8 Centrifree® ultrafiltration devices for plasma protein binding study 
(Millipore Centrifree® Ultrafiltration Devices Instructions) 
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3.2.3.2 Determination of fraction unbound in DEX-spiked blank samples  
Stock solutions of DEX (1 mg/mL) in methanol were added to blank pregnant ewe and 
fetus plasma, respectively, to provide maternal and fetal plasma samples at different 
concentrations over the respective concentration ranges relevant to those in pregnant 
ewe and fetus samples of pharmacokinetic studies in Section 3.2.2. Aliquots of plasma 
were placed in a rolling incubator at 37 °C for 30 min to ensure that equilibrium was 
established. Following incubation, two hundred μL aliquots of the spiked plasma 
samples were added into the sample reservoir of ultrafiltration unit. The plasma samples 
were then centrifuged with fixed angle rotor at 1,000 g (37 °C) for 30 min. Fifty μL of 
ultrafiltrate from the filtrate cup was transferred for sample preparation and analysis.  
3.2.3.3 Determination of the extent of nonspecific binding 
Nonspecific binding (NSB) of DEX onto the YM-30 Centrifree® ultrafiltration filter 
membrane and plastic devices was determined by using PBS samples at three DEX 
concentrations of 100, 500 and 2500 pg/ml. The PBS samples were prepared by the 
same procedure described in Section 3.2.3.2.  
3.2.3.4 Sample preparation and analysis 
The sample extraction and reconstitution procedures previously described in Section 
3.2.1.5 were followed. After sample preparation, aliquots of samples (10-20 µL) were 
analyzed using the modified LC-MS/MS assay with an advanced mass spectrometer of 
AB Sciex 5500 QTRAP® that can achieve a LLOQ of 10 pg/mL. 
All experimental procedures were performed with more than three replicates, and NSB 
and fu were reported as mean with standard deviation (SD) unless otherwise noted. 
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Statistical analysis was performed using two-tailed Student’s t test between two mean 
values or one-way ANOVA with post-hoc Tukey’s test among mean values more than 
two groups. A probability of less than 0.05 (p < 0.05) was considered to be statistically 
significant. 
3.2.3.5 Plasma protein binding (%) calculation 
NSB of ultrafiltration units was determined from the measured concentrations of filtrate 
and PBS samples using the following equation: 
% NSB = (1 −  
𝐶𝑝𝑏𝑠𝑢𝑓
𝐶𝑝𝑏𝑠
) × 100% 
Where Cpbs is the (total) drug concentration in the initial PBS solution before 
centrifugation and Cpbsuf is the drug concentration in the PBS ultrafiltrate after 
centrifugation. When Cpbsuf = Cpbs, NSB is 0, and there is no need of NSB correction for 
the protein binding calculation. When Cpbsuf < Cpbs, it can be assumed that a fraction of 
drug disappeared in UF. The NSB correction of plasma protein binding was calculated 
as follows: 
% fu =  
𝐶𝑝_𝑢𝑓
(1 − 𝑁𝑆𝐵) ∙ 𝐶𝑝
× 100% 
% PPB =  (1 − fu) × 100% 
Where fu is the free fraction, Cp_uf is the drug concentration in the plasma filtrate, and 
Cp is the nominal plasma concentration.  
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3.2.4. In vitro UGT metabolism  
3.2.4.1 Preparation of liver and placental microsomes 
Blank placenta and liver samples from pregnant ewes and fetuses were supplied by 
Texas Children’s Hospital, Baylor College of Medicine (Houston, TX, USA). Microsomes 
were prepared using a procedure adopted from the literature with minor modifications as 
described below (Chen J et al., 2003). Briefly, organ samples were thawed and then 
minced on a glass plate placed on ice with a sharp and clean blade to make the samples 
ready for homogenization. The minced organ samples were then transferred into 10 ml 
cylindrical homogenization glass tubes placed on ice. The livers were then homogenized 
using a motorized homogenization gun fitted with a Teflon pestle in ice-cold 
homogenization buffer comprised of 10 mM potassium phosphate solution (pH 7.4), 250 
mM sucrose and 1 mM EDTA.  
The mixture was then transferred into clean polycarbonate centrifuge tubes and 
centrifuged at 10,500 rpm at 4°C for 15 min. The pellet which contained cell debris and 
unwanted waste was discarded and the supernatant was collected into clean 
polycarbonate ultracentrifuge tubes and centrifuged again at 35,000 rpm at 4°C for 60 
min. The fat layer on the top was carefully aspirated using rubber droppers to yield the 
microsomal pellets. The microsomal pellets were then washed three times with 250 mM 
sucrose and resuspended in 250 mM sucrose by manually homogenizing and grinding 
the microsomal pellets with a Teflon pestle. The final liver or placental microsomes were 
stored frozen at -80 °C until the use for study of DEX metabolism. Protein concentration 
was determined using a BCA protein assay kit with bovine serum albumin (BSA) as the 
standard. 
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3.2.4.2 BCA assay for protein quantification 
Microsomes were placed on ice all the time during the experiment. Working reagent was 
prepared by mixing Reagent A (bicinchonic acid and tartrate in an alkaline carbonate 
buffer) with Reagent B (4% copper sulfate pentahydrate solution) in the BCA protein 
assay kit at a ratio of 50:1 as per the manufacturer’s recommendation. Triplicate 10 μL of 
the microsome samples were added to the working reagent (190 μL) in 1.5-mL tubes. 
The standards of protein concentrations were prepared from the stock of 2 mg/mL with 
the working reagent to get final concentrations of 0.1, 0.2, 0.4, 0.6, 0.8 and 1 mg/mL 
respectively. Two hundred μL of working reagent containing the samples or standards 
was then transferred into a clear bottom 96 well plate. The plate was covered with 
aluminum foil and incubated at 37 °C for 30 min. After incubation, the plate was read on 
a Biotek plate reader for the absorbance at 570 nm to determine the microsomal protein 
concentrations. 
3.2.4.3 Enzyme assays 
The enzyme assay procedures for measuring UGTs’ activities were the same as 
previously published in the literature (Joseph TB et al., 2007; Liu X et al., 2007; Tang L 
et al., 2009). A final mixture for incubation procedures comprised of liver or placental 
microsomes (final concentration in range of 0.0053-0.053 mg of protein per mL as 
optimum for reaction), alamethicin (0.022 mg/mL), saccharolactone (4.4 mM), 
magnesium chloride (0.88 mM), different concentrations (1.25-50 μM) of substrate in a 
50 mM potassium phosphate buffer (pH 7.4), and UDPGA (3.5 mM, added the last). The 
mixture (200 μL) was incubated at 37°C for predetermined periods of time and the 
reaction was stopped by adding acetonitrile/acetic acid (94:6) containing 100 μM 
testosterone (IS). Pooled human liver microsomes (pHLM) were used as the positive 
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control, whereas the negative control was the sample with the same amount of 
potassium phosphate replacing microsomes. Genistein, a typical known substrate of 
UGT, was used to investigate the UGT activities in pregnant ewe model.   
3.2.4.4 UPLC analysis and confirmation of glucuronide structures by LC-MS/MS 
Parent compounds and their generated glucuronides were analyzed using a Waters 
UPLC system. DEX and its glucuronide were separated and identified using the LC-
MS/MS assays in Section 3.2.1 with minor modifications. The detect transition ion from a 
specific precursor ion to product ion [M+H]+ for DEX glucuronide is m/z 377.1 → 201.5. 
The collision energy was set at 22 eV for the DEX glucuronide.  
Genistein and its glucuronide were analyzed by UPLC with photodiode array detector 
and Empower software, using the following method that was described in the literature 
(Liu Y et al., 2002; Tang L et al., 2009). Briefly, the mobile phase A is 0.5% formic acid in 
water and mobile phase B is 100% acetonitrile. The elution was achieved with a BEH 
C18 column (1.7 μm, 2.1 × 50 mm).  Mobile phase was eluted for 5 min at a flow rate of 
0.5 ml/min with gradient (10% B at 0 to 0.3 min, 10–50% B at 0.3 to 2 min, 50–90% B at 
2 to 3.5 min, 90% B at 3.5 to 4.0 min, 90-10% at 4.0 to 4.5 min, and 10% B at 4.5 to 5 
min). Samples of 10 μL were injected into UPLC for analysis. Genistein and its 
glucuronide were detected and quantified at the wavelength of 254 nm. The LLOQ was 
0.78 μM (Tang L et al., 2009).  
3.2.4.5 Kinetic analysis 
Metabolism rates in liver and placental microsomes were expressed as amounts of 
metabolites formed per min per mg protein (nmol/min/mg). Kinetic parameters (Vmax and 
Km) were estimated by fitting the Michaelis-Menten and/or atypical profiles equations to 
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the substrate concentrations and initial rates. Eadie-Hofstee plots were used to confirm 
the kinetic model selection. If the Eadie-Hofstee plot was linear, the standard Michaelis-
Menten equation could be used to fit the glucuronides formation rates (V) at different 
substrate concentrations (C). 
𝜈 =  
𝑉𝑚𝑎𝑥  × 𝐶
𝐾𝑚 + 𝐶
 
If Eadie-Hofstee plots showed characteristic profiles of atypical kinetics (e.g. biphasic 
kinetics), atypical profiles equations, such as the Hill equation (
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could be used to adequately fit the data using SigmaPlot. Akaike's information criterion 
(AIC) and R2 values were used to evaluate the goodness-of-fit of each model. 
3.2.5. Pharmacokinetic/pharmacodynamic modeling 
3.2.5.1 Phoenix NLME 
Pharmacokinetic analysis was performed by a nonlinear mixed-effect modeling 
approach, using Phoenix NLME software (nonlinear mixed-effects, version 1.3). This 
NLME modeling could provide a good solution for modeling sparse datasets with 
deviated sampling time and/or missing samples. These models also account for both 
fixed effects (population parameters assumed to be constant each time when data are 
collected) and random effects (sample-dependent random variables). 
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3.2.5.2 Pharmacokinetic modeling of free and total DEX 
The pharmacokinetic model was developed based on the data collected from a total of 
eight pregnant ewes and twelve fetuses in Section 3.2.2. Model development and 
simulation were performed using the first-order conditional estimation with η-σ 
interaction. The pharmacokinetics of free and total DEX concentrations in pregnant ewe 
and fetus were studied sequentially, described as follows: (1) the pharmacokinetics of 
DEX in pregnant ewes were investigated; (2) the fetal data were connected to the 
pregnant ewe model, and the corresponding parameters in fetus were estimated, but the 
maternal parameters were fixed; (3) protein binding model was evaluated to describe the 
relationship between free and total DEX plasma concentrations; and (4) all the 
parameters of the integrated model were estimated simultaneously for free and total 
DEX data from both pregnant ewe and fetus.  
For the maternal data, one-, two- and three-compartment models were tested. For fetal 
concentrations, two models were tested: (a) an additional compartment linked to 
maternal compartment and (b) an effect compartment of negligible volume linked to the 
maternal circulation by first-order processes to the maternal circulation. Nonlinear and 
linear protein-binding models were considered for describing the relationship between 
free and total DEX concentrations.  
Estimation of individual PK parameters was assumed to follow a log-normal distribution. 
Therefore exponential distribution models were used to describe the intersubject 
variability as follows: 
𝑃𝑖  =  𝑃 ∙ 𝑒𝑥𝑝(𝜂𝑖) 
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Where Pi is the individual parameter estimate for individual i, P is the typical population 
parameter estimate, and 𝜂 i was assumed to be distributed N (0, ω2). Only significant 
intersubject variability in pharmacokinetic parameters was retained.  
Residual unexplained variability was implemented as either a proportional or combined 
error model: 
𝐶𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑,𝑖𝑗 =  𝐶𝑝𝑟𝑒𝑑,𝑖𝑗 × (1 +  𝜀𝑝,𝑖𝑗) +  𝜀𝑎,𝑖𝑗 
Where Cobserved,ij represents the observed concentration for individual i and observation j, 
Cpred,ij represents the individual predicted concentration, and εp,ij and εa,ij represent the 
proportional and additive errors distributed following N (0, σ2). The residual error model 
was selected based on the likelihood ratio tests as well as evaluation of the goodness-
of-fit diagnostic plots. 
3.2.5.3 Model selection and evaluation 
To determine an appropriate PK model, model discrimination and identification of 
variability were based on evaluations of the -2 ×  log likelihood (-2LL) of the data, 
plausible parameter estimates, and adequate parameter precision, as well as evaluation 
of diagnostic plots. A difference in -2LL of at least 3.84 (corresponding to p < 0.05) was 
used to discriminate between competing models. The accuracy of the final model was 
tested with a bootstrap method in Phoenix NLME, based on the random resampling from 
the original data. The resampling was repeated sufficiently to meet FDA guidelines (FDA 
Guidance for Industry - Population Pharmacokinetics, 1999). Predicted parameters 
obtained from the bootstrap validation were compared to the estimates from the original 
data. 
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3.2.5.4 Pharmacodynamic modeling 
Pharmacodynamic models were also analyzed by Phoenix (version 1.3). The observed 
pharmacodynamic effects of blood pressure and heart rate were linked to predicted 
maternal and fetal plasma concentrations via a sigmoidal Emax model:  
𝐸 =  𝐸0 +  
𝐸𝑚𝑎𝑥 ∙  𝐶𝑒
𝑛
𝐶𝑒
𝑛  +  𝐸𝐶50
𝑛  
Where E0 is the baseline effect, Emax is the maximal effect, EC50 is the effect-site 
concentration that could produce half of the maximum response, n is a slope factor and 
E is the estimated effect at effect-site concentration of Ce. The effect-site concentration 
is assumed to be the same as the plasma concentration at steady-state. 
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Chapter 4 Results 
 
 
The results of this investigation are summarized in the following six subtopics: (1) 
Development and validation of LC-MS/MS assay for quantification of DEX in the 
pregnant ewe model, (2) Maternal and fetal pharmacokinetics of DEX after intravenous 
administration to pregnant ewes, (3) Pharmacodynamic studies of DEX in pregnant ewe 
and fetus; (4) In vitro plasma protein binding assay, (5) UGT metabolism of DEX with 
liver and placental microsomes, and (6) Pharmacokinetic and pharmacodynamic models 
of DEX in pregnant ewe model.  
4.1. LC-MS/MS assay for quantification of DEX in plasma 
4.1.1. LC Chromatographs  
No significant interfering peaks from plasma endogenous components were present at 
the retention time of DEX (3.20 min) or IS (3.56 min). The LLOQ for DEX was 25 pg/mL 
with a 3200 QTRAP mass spectrometer. The chromatograms for blank plasma, and 
blank plasma samples spiked with DEX at LLOQ are shown in Figure 9 for pregnant 
ewe and in Figure 10 for fetus, respectively. A lower LLOQ of 10 pg/mL was achieved 
with a 5500 QTRAP mass spectrometer. 
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Figure 9 Chromatograms of DEX with LLOQ (25 pg/mL) in maternal plasma 
DEX 
Internal Standard 
Double Blank 
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Figure 10 Chromatograms of DEX with LLOQ (25 pg/mL) in fetal plasma 
 
 
 
 
 
 
DEX 
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Double Blank 
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4.1.2. Linearity of calibration curves 
The assay exhibited excellent linear response over the selected concentration ranges 
(25-5000 pg/mL in plasma) by linear regression analysis (Figure 11). Inter-day assay 
variability of the calibration curves from six different sources was presented in Table 5. 
Correlation coefficients (r2) from inter-day batches over calibration curves were greater 
than 0.99. 
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Figure 11 Calibration curves of DEX in maternal plasma (R² = 0.9985) and fetal 
plasma (R² = 0.9993) 
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Table 5 Linearity of calibration curves for DEX (n=6) 
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4.1.3. Accuracy and precision 
Data of intra- and inter-day accuracy and precision for DEX are summarized in Table 6. 
The intra-day accuracy and precision, based on the coefficient variation replication for 
QC samples, ranged from 97.7 to 100.0% and 3.3 to 5.2% in maternal plasma, 
respectively, and 98.2 to 102.6% and 3.1 to 5.0% in fetal plasma, respectively. The inter-
day accuracy and precision ranged from 94.8 to 100.1% and 4.5 to 5.6% in maternal 
plasma, respectively, and 99.5 to 100.2% and 4.2 to 6.0% in fetal plasma, respectively. 
These data revealed that the developed assay was accurate and reproducible.  
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Table 6 Accuracy and precision of DEX at three levels of QC samples 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nominal 
Conc. 
(pg/mL) 
Intra-day Batch (n=6) Inter-day Batch (n=18) 
Accuracy (%) Precision (%) Accuracy (%) Precision (%) 
Maternal Plasma 
50 98.73 5.24 94.80 5.64 
500 100.02 3.27 100.07 5.37 
2500 97.73 3.25 100.03 4.50 
Fetal Plasma 
50 102.60 3.10 100.20 4.53 
500 99.17 4.38 99.97 5.99 
2500 98.21 4.97 99.52 4.19 
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4.1.4. Recovery and matrix effect 
The mean (±SD) extraction recoveries and matrix effects on DEX are tabulated in Table 
7. In maternal plasma samples, extraction recoveries at 50, 500 and 2500 pg/mL were 
83.7±2.5%, 87.2±3.4% and 82.9±2.5%, respectively, while in fetal plasma samples, 
extraction recoveries at 50, 500 and 2500 pg/mL were 86.2±2.5%, 89.7±3.1% and 
88.4±0.8%, respectively. The CV % for all recoveries were less than 3.9% indicating the 
extraction efficiency for DEX using liquid-liquid extraction was consistent and 
reproducible. The mean (±SD) percentage matrix factors were 110.8 ± 11.4% and 101.3 
± 7.5% in maternal and fetal plasma, respectively. No significant difference in matrix 
effect was observed between maternal and fetal plasma samples, and the effects were 
concentration-independent in the tested concentration ranges. These indicated a low ion 
enhancement and that the analytical method is free from significant interference from 
endogenous substances in plasma.  
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Table 7 Recovery and matrix effect of DEX in pregnant ewes and fetuses (n=6) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nominal Conc. 
(pg/mL) 
Recovery of Extraction (%) Matrix Effect (%) 
Mean ± SD (%) CV (%) Mean ± SD (%) CV (%) 
Maternal Plasma  
50 83.74±2.48 2.96 122.6±8.35 6.81 
500 87.23±3.40 3.89 110.0±4.68 4.26 
2500 82.92±2.48 2.98 99.82±7.39 7.40 
Overall 84.63±2.29 2.70 110.8±11.4 10.29 
Fetal Plasma  
50 86.17±2.49 2.88 107.3±7.20 6.71 
500 89.67±3.07 3.42 92.86±5.46 5.88 
2500 88.35±0.80 0.91 103.5±10.7 10.35 
Overall 88.06±1.77 2.01 101.3±7.51 7.42 
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4.1.5. Stability 
The stability experiments were designed based on the expected conditions during the 
sample storage and processing procedures. Each stability test included three replicates 
of three levels of QC samples. The stability data under various storage and process 
conditions are presented in Table 8. The results of freeze and thaw stability experiment 
indicated that DEX was stable in plasma (95.6-103.4%) for three cycles when stored at - 
80°C and thawed to room temperature. The results of the post-preparative stability study 
confirmed that DEX could be analyzed for 24 h in the autosampler tray at 20°C with 
96.0-102.9% of nominal concentration. In addition, the short-term stability result ensured 
reliable stability (94.8-101.5%) for 3 h under the sample preparation procedures at room 
temperature. 
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Table 8 Stability of DEX under various conditions (n=3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nominal Conc. 
(pg/mL) 
Mean (± SD) Percent of Nominal Conc. 
Freeze/Thaw Stability 
Three Cycles, - 80°C 
Post-preparative Stability 
Autosampler, 20 °C, 24 h 
Short-term Stability 
Sample at RT, 3 h 
Maternal Plasma    
50 95.61±4.95 100.84±3.34 101.51±2.72 
500 101.34±1.56 102.93±1.68 94.79±2.08 
2500 97.54±2.37 95.96±5.56 96.29±4.28 
Fetal Plasma    
50 98.55±0.91 100.60±0.82 95.42±1.36 
500 100.78±3.75 99.63±1.05 98.68±5.08 
2500 103.35±3.90 99.88±4.27 95.19±1.52 
    
. ±1.56 
±3.34 
±1.68 
. ±2.72 
.8±3.75 
.4±3.90 
±0.82 
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4.2. Pharmacokinetics of DEX in pregnant ewe and fetus 
Pharmacokinetic experiments were completed in all eight third-trimester ewes (mean 
weight 72.8 ± 11.0 kg) and their twelve fetuses. Complete paired pharmacodynamic data 
were obtained in four maternal-fetal units. 
4.2.1. Plasma concentration-time profiles 
A total of 107 DEX concentrations measured above the LLOQ were included in the PK 
evaluation, among which 47 and 21 concentrations were from maternal artery and vein, 
respectively, and 62 and 19 concentrations were from fetal arterial and vein, 
respectively. Maternal and fetal concentrations ranged from 29.8 to 6197.9 pg/mL, and 
from 8.0 to 265.0 pg/mL, respectively. The mean (± SD) plasma DEX concentration-time 
profiles in maternal arterial and venous blood, as well as those in fetal arterial and 
venous blood are depicted in Figure 12.  
DEX concentration profiles in maternal arterial and venous blood were similar except in 
one ewe at early time points with three extremely high venous concentrations that 
resulted in large variations in the maternal concentrations during infusion with a 
coefficient of variation (CV%) = 141.1%, whereas the fetal concentrations during infusion 
were relatively constant with a CV% of 48.0%. The fetal arterial and venous DEX 
concentration profiles were comparable. 
At the end of the loading dose (10 min), DEX concentrations in maternal artery and fetal 
vein were 815.1±497.2 and 104.5±40.3 pg/mL, respectively. This indicated a rapid 
transplacental transfer of DEX after drug administration to the pregnant ewe. At 70 min 
(the end of the one hour infusion), maternal DEX concentrations started declining rapidly 
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for 1 h (at 130 min), followed by a slower decline. On the other hand, fetal DEX levels 
remained relatively constant, markedly lower than those in the pregnant ewe before one 
hour post the end of infusion.  
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Figure 12 Mean (± SD) DEX concentration-time profiles for pregnant ewes (n=8) 
and fetuses (n=12). Line a: end of loading dose and Line b: end of 
infusion. 
 
M-A: maternal arterial concentrations 
M-V: maternal venous concentrations excluding 3 high concentrations during 
infusion in one ewe (3 MV conc. in 1 subject, shown as open circles) 
F-A: fetal arterial concentrations 
F-V: fetal venous concentrations 
 
 
 
a b 
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4.2.2. Non-compartmental pharmacokinetic analysis 
Data of maternal and fetal arterial concentrations were sequentially used for non-
compartmental PK analysis. The estimates of PK parameters for individual ewes and 
fetuses are tabulated in Table 9. The Cmax of DEX was 778.1 ± 398.4 and 143.6 ± 86.6 
pg/mL in pregnant ewe and fetus, respectively. The tmax (time to reach the Cmax) occurred 
at approximately 40 and 47.5 min (70 min, at the end of infusion for four subjects and 10 
min for the other four subjects) in pregnant ewe and fetus, respectively.  The maternal 
and fetal AUCt were 61.8 ± 22.5 and 20.5 ± 11.9 ng/(mL*min), respectively. The 
maternal CL and V were 38.64 ± 17.72 mL/(min*kg) and 3357.6 ± 1292.2 mL/kg, 
respectively. The Cmax and AUCt between pregnant ewes and fetuses were statistically 
different, whereas t1/2 was not.   
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Table 9 Pharmacokinetic parameters by non-compartmental analysis of arterial 
concentration in pregnant ewes (n=8) and fetuses (n=12) 
 
 
Unit Pregnant Ewe Fetus 
tmax min 40.0 ± 32.1 47.5 ± 29.0 
*Cmax pg/mL 778.1 ± 398.4 143.6 ± 86.6 
*AUCt ng/(mL*min) 61.8 ± 22.5 20.5 ± 11.9 
AUC∞ ng/(mL*min) 69.5 ± 21.1 34.9 ± 20.7 
t1/2 min 63.62 ± 24.0 143.6 ± 86.6 
CL mL/(min*kg) 38.64 ± 17.72 -- 
V L/kg 3.36 ± 1.29 -- 
 
Note: 
* indicates values are significantly different between pregnant ewes and fetuses by 
Student’s t-test at p<0.05.  
-- indicates values that cannot be derived because the amount of DEX transferred to the 
fetus is unknown. 
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4.2.3. Placental transfer of DEX 
The placental transfer partition coefficient (KFM) of DEX from the pregnant ewe to the 
fetus is calculated by AUC ratios between fetuses and ewes, and is shown in Table 10. 
KFM was 0.13 ± 0.10 and 0.13 ± 0.08 at 10 min and 70 min respectively. Distributions in 
mothers and fetuses reached equilibrium rapidly. At 250 min, three hours after the end of 
infusion, KFM reached 0.23 ± 0.14. Based on the placental transfer partition ratio (KFM), 
the fetal exposure to DEX was approximately 23% of maternal exposure.  There was no 
statistical difference among the KFM at any of the time points.  
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Table 10 KFM from pregnant ewe (n=8) to fetus (n=12) at different time points 
 
Time (min) KFM 
10 0.13 ± 0.10 
20 0.15 ± 0.11 
40 0.13 ± 0.17 
70 0.13 ± 0.08 
130 0.16 ± 0.10 
190 0.20 ± 0.15 
250 0.23 ± 0.14 
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4.3.  Pharmacodynamics of DEX in pregnant ewe and fetus 
Pharmacodynamics of blood pressure and heart rate in pregnant ewe and fetus after 
drug administration are shown in Figures 13 and 14, respectively. Significant decreases 
were observed in maternal diastolic blood pressure and maternal heart rate. Pregnant 
ewes exhibited a 30% decrease in mean arterial pressure (MAP) with a clinically 
significant difference between the MAP at baseline and MAP at 120 min of the study 
(Figure 15). An approximately 50% decrease in heart rate upon administration of DEX 
was observed which continued throughout the period of drug administration. This 
decrease in heart rate was statistically significant between baseline and 120 min. In 
contrast, only a negligible decrease in the MAP (1%) and a 16% decrease in the heart 
rate of the fetus were observed with fetal exposure to DEX. While decreases in both 
parameters continued to be observed over the initial 2 h period of the study; 14% and 
12% reduction in fetal MAP and heart rate, respectively, after 2 h of drug administration, 
both values remained within clinically normal parameters and were not statistically 
significant compared to the values at baseline. Table 11 summarizes arterial blood gas 
values obtained at baseline and 120 min. Decreases in fetal arterial oxygen content and 
an increase in fetal metabolic acidosis were noted by the conclusion of the study, but 
these changes were not statistically significant between baseline and 120 min. 
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Figure 13 Mean (±SD) blood pressure profiles of pregnant ewe and fetus (n=4) 
 
 
SBP-M: maternal systolic blood pressure 
DBP-M: maternal diastolic blood   pressure 
SBP-F: fetal systolic blood pressure 
DBP-F: fetal diastolic blood pressure 
 
Note: 
* indicates values are significantly different compared to values at baseline by one-way 
ANOVA with post hoc Tukey’s test at p<0.05 
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Figure 14 Mean (±SD) heart rate profiles of pregnant ewe and fetus (n=4) 
 
 
HR-M: maternal heart rate 
HR-F: fetal heart rate 
 
Note: 
* indicates values are significantly different compared to values at baseline by one-way 
ANOVA with post hoc Tukey’s test at p<0.05 
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Figure 15 Mean (±SD) profiles of cardiovascular effects (percentage change) 
 
 
MAP-M: maternal mean arterial pressure 
MAP-F: fetal mean arterial pressure  
HR-M: maternal heart rate 
HR-F: fetal heart rate  
 
 
Note: 
* indicates values are significantly different compared to values at baseline by one-way 
ANOVA with post hoc Tukey’s test at p<0.05 
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Table 11 Arterial blood gas at baseline and 120 min (n=4) 
 
 
 
Baseline 120 min 
 
Pregnant Ewe Fetus Pregnant Ewe Fetus 
pH 7.42 ± 0.12 7.31 ± 0.06 7.56 ± 0.13 7.13 ± 0.12 
PaO2 279 ± 139 21 ± 2 338 ± 109 13 ± 6 
PaCO2 43 ± 14 59 ± 23 39 ± 14 84 ± 29 
SaO2 99.6 ± 0.5 31.3 ± 2.5 99.9 ±  0.1 12 ± 12 
BE 5.8 ± 4.6 4.3 ± 5.6 6.7 ± 4.0 -1.4 ± 9.2 
HCO3 29.5 ± 5.8 30.2 ± 6.6 29.7 ± 5.1 26.0 ± 6.0 
     
SaO2: Oxygen Saturation 
 
BE: Base Excess 
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4.4. Plasma protein binding assay 
Nonspecific binding (NSB) was determined as 17.8 ± 2.1 % (n=3) at three concentration 
levels of 100, 500 and 2500 pg/ml in PBS (Table 12). The calibration curves containing 
5 concentration points were constructed at the linearity range of 50-2500 pg/mL in PBS 
with correlation coefficients > 0.999 (Figure 16). 
Fractions of unbound (fu) DEX in pregnant ewe and fetus were 25.1 ± 4.8 % (n=4-7) and 
38.9 ± 3.2 % (n=3), respectively. Therefore, the extents of plasma protein binding (PPB) 
were 74.9 ± 4.8 % for pregnant ewe, significantly higher than those in fetus (61.1 ± 3.2 
%) (Table 13), and were concentration-independent over the respectively selected 
concentration ranges of 50-2500 pg/mL for maternal samples and 50-200 pg/mL for fetal 
samples (Figure 17).  
The fu in DEX-spiked blank plasma of pregnant ewe (27.2 ± 3.3 % for 50pg/mL and 24.2 
± 5.0 % for 100pg/mL) were significantly lower (p<0.05) than those in fetal plasma, 38.5 
± 3.5 % for 50 pg/mL and 39.6 ± 3.4 % for 100 pg/ml (Table 13 and Figure 18).  
The PPB in PK samples was determined in 26 maternal samples and 24 fetal samples 
from four pregnant ewes. The mean (± SD) fu of PK samples were 19.6 ± 3.9 % for 
pregnant ewe, also significantly lower than the fu in fetus, 36.9 ± 4.8 % (Figure 19). 
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Table 12 Nonspecific binding with the Centrifree® device (n=3) 
 
Nominal Conc. 
(pg/ml) 
Ultrafiltrate Conc. 
(pg/ml) 
Recovery 
(%) 
NSB 
(%) 
Overall 
(%) 
100 82.1 ± 4.3 82.1 17.9 
17.8 ± 2.1 
500 409.4 ± 5.5 81.9 18.1 
2500 2064.1 ± 76.9 82.6 17.4 
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Figure 16 Calibration curve of DEX in PBS (R² = 0.9997) for nonspecific binding 
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Table 13 Plasma protein binding assay of fraction unbound DEX 
 
 
Note: 
* indicates values are significantly different between pregnant ewes and fetuses by 
Student’s t-test at p<0.05.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cp 
(pg/ml) 
Pregnant Ewe Fetus 
Mean SD N Mean SD N 
50 27.2 3.3 6 38.3* 3.5 3 
100 24.2 5.0 7 39.6* 3.4 3 
200 -- -- -- 39.1 2.7 3 
250 23.5 3.4 3 -- -- -- 
500 28.8 6.4 4 -- -- -- 
1000 27.4 4.3 6 -- -- -- 
2500 23.9 4.2 6 -- -- -- 
Overall 25.1 4.8 32 38.9* 3.2 9 
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Figure 17 Fractions unbound (%) in DEX-spiked (a) maternal plasma, and (b) fetal 
plasma over selected ranges 
 
 
Note: 
 
No significant difference among samples within pregnant ewe and fetus groups, 
respectively by one-way ANOVA with Tukey’s post hoc test at p<0.05 
 
 
 
a. 
b. 
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Figure 18 Fractions unbound (%) DEX at concentrations of 50 and 100 pg/ml in 
pregnant ewe and fetus. * Two-tailed t-test at p<0.05. 
* 
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Figure 19 Fractions unbound (%) DEX in PK samples. N indicated the number of samples for each pregnant ewe and fetus. 
Significant differences were evaluated by Student’s t-test at p<0.01. 
* * 
* * 
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4.5. UGT metabolism of DEX in pregnant ewe and fetus 
4.5.1. Negligible N-glucuronidation of DEX in the pregnant ewe model 
The Waters ACQUITY UPLC (Ultra performance liquid chromatography) system was 
used to analyze DEX and its corresponding glucuronide conjugate. Representative 
chromatograms and UV spectra were shown in Figure 20. The DEX and IS peaks were 
observed at the retention times of 1.86 and 2.25 min, respectively, at the wavelength of 
214 nm (Figure 21). The calibration curve of DEX in potassium phosphate buffer (KPI) 
with linear range of 1.06 - 42.2 μM is shown in Figure 22. Correlation coefficient (R2) of 
the calibration curve was greater than 0.99 indicating an excellent linear response over 
the selected concentration range. Very few or no DEX glucuronidation metabolites were 
identified after the incubation of DEX (10 μM in final mixture) with hepatic microsomes 
prepared from pregnant ewe and fetus, as well as that from placenta, respectively. The 
negligible DEX glucuronide concentrations were also confirmed by the same UPLC 
system coupled with a mass spectrometer. DEX glucuronide structure was not 
detectable (Figures 23-25). The DEX and IS peaks were observed at the retention times 
of 2.62 and 3.12 min, respectively. 
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Figure 20 UV spectra of (a) DEX and (b) IS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a. 
b. 
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Figure 21 Chromatograms of DEX and IS (a) with and (b) without pregnant ewe 
liver microsomes after 12 h-incubation 
 
 
 
 
 
 
 
 
 
 
a. 
b. 
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Figure 22 Calibration curve of DEX in KPI buffer (R² = 0.9974) 
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Figure 23 LC-MS/MS chromatograms of (a) DEX and IS, (b) extracted ion chromatograms (XIC) of DEX glucuronide (m/z: 
377→201) in liver microsomes prepared from pregnant ewe.  
a. 
b. 
No DEX Glucuronide 
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Figure 24 LC-MS/MS chromatograms of (a) DEX and IS, (b) XIC of DEX glucuronide (m/z: 377→201) in liver microsomes 
prepared from fetus.  
 
a. 
b. 
No DEX Glucuronide 
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Figure 25 LC-MS/MS chromatograms of (a) DEX and IS, (b) XIC of DEX glucuronide (m/z: 377→ 201) in placental 
microsomes. 
a. 
b. 
No DEX Glucuronide 
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4.5.2. DEX glucuronidation by human liver microsomes 
In contrast, DEX glucuronide was observed at 1 h with pHLM (pooled human liver 
microsomes) of the same protein concentration. Figure 26 demonstrated the 
representative chromatogram of DEX and DEX glucuronide after 24 hr incubation with 
pHLM. The DEX, DEX-Glucuronide and IS peaks were observed at the retention times 
of 2.62, 2.42 and 3.12 min, respectively. This indicated that N-glucuronidation is a 
negligible pathway for DEX in pregnant ewe which differs from that in humans. 
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Figure 26 LC-MS/MS chromatograms of (a) DEX and IS, (b) XIC of DEX glucuronide (m/z: 377→201) in pHLM 
a. 
b. 
DEX Glucuronide 
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4.5.3. Differential UGT activities in hepatic microsomes between pregnant 
ewe and fetus 
Differential UGT activities in liver microsomes between pregnant ewe and fetus were 
characterized by using genistein as a reference substrate. The optimal reaction time for 
genistein with maternal and fetal liver micromsomes was determined to be 30 and 40 
min, respectively, based on the results of a time-course study. Final genistein 
concentrations at 1.25, 2.5, 5, 10, 15, 20, 35 and 50 μM were investigated for evaluation 
of kinetic profiles.  
4.5.3.1 UPLC analysis 
The Waters ACQUITY UPLC (Ultra performance liquid chromatography) system was 
used to analyze genistein and its corresponding glucuronide. Representative 
chromatograms and UV spectra are shown in Figure 27. The genistein, genistein 
glucuronide and IS peaks were observed at the retention times of 2.04, 1.74 and 2.25 
min, respectively, at the wavelength of 260 nm (Figure 28 in pregnant ewe and Figure 
29 in fetus). A calibration curve for genistein in KPI buffer with a linear range of 0.5 - 50 
μM is shown in Figure 30. The correlation coefficient (R2) of the calibration curves was 
greater than 0.99 indicating an excellent linear response over the selected concentration 
range. Genistein and its glucuronide chemical structures were also confirmed by an LC-
MS/MS assay (Figures 31 & 32). 
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Figure 27 UV spectra of (a) genistein, (b) genistein glucuronides and (c) IS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a. 
b. 
c. 
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Figure 28 Chromatograms of genistein, genistein glucuronide and IS (a) with and 
(b) without maternal liver microsomes after 30 min-incubation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a. 
b. 
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Figure 29 Chromatograms of genistein, genistein glucuronide and IS (a) with and 
(b) without fetal liver microsomes after 40 min-incubation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a. 
b. 
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Figure 30 Calibration curve of genistein in KPI buffer (R² = 0.9989) 
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Figure 31 LC-MS/MS chromatograms of (a) genistein, genistein glucuronide and IS, (b) XIC of genistein glucuronide 
(m/z: 445.0→268.9) in liver microsomes prepared from pregnant ewe. 
Genistein Glucuronide 
b. 
a. 
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Figure 32 LC-MS/MS chromatograms of (a) genistein, genistein glucuronide and IS, (b) XIC of genistein glucuronide 
(m/z: 445.0→268.9) in liver microsomes prepared from fetus. 
Genistein Glucuronide 
a. 
b. 
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4.5.3.2 Kinetic study 
Kinetic parameters (Vmax, Km) were estimated by fitting the initial rate data to Michaelis-
Menten and atypical kinetic rate equations by nonlinear least-squares regression. The 
goodness-of-fit was evaluated on the basis of AIC and R2 values. Table 14 summarizes 
the kinetic analysis after using the Michaelis-Menten, substrate inhibition, sigmoidal Hill 
and biphasic two sites equations. Figure 33 and 34 show the kinetic plots of genistein 
after metabolism incubation with different concentrations of genistein in maternal and 
fetal liver microsomes, respectively. These results indicated that genistein follows the 
biphasic kinetic metabolic pattern in both pregnant ewe (Figure 33) and fetus (Figure 
34), with the respective apparent Km,1 of 1.45 and 1.79 μM, and Vmax,1 of 28.03 and 1.49 
nmol/min/mg of protein, respectively. Eadie-Hofstee plots were used to confirm the 
biphasic kinetics. In human liver microsomes, genistein glucuronidation also follows the 
biphasic kinetics with Km,1 of 0.026 μM and Vmax,1 of 2.5 nmol/min/mg of protein (Figure 
35).  
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Table 14 Kinetic analysis of genistein glucuronidation with different models 
(n=3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kinetic Model 
AIC  R2 
Pregnant Ewe Fetus  Pregnant Ewe Fetus 
Michaelis-Menten -32.04 -97.1  0.94 0.91 
Substrate Inhibition -34.95 -94.2  0.94 0.91 
Hill Equation -18.23 -118.1  0.97 0.97 
Biphasic Two Sites -10.56 -130.9  0.98 0.98 
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Figure 33 (a) Kinetics of genistein glucuronidation by maternal liver microsomes 
and (b) corresponding Eadie-Hofstee plot (n=3) 
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Figure 34 (a) Kinetics of genistein glucuronidation by fetal liver microsomes and 
(b) corresponding Eadie-Hofstee plot (n=3)  
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Figure 35 (a) Kinetics of genistein glucuronidation by pooled human liver 
microsomes and (b) corresponding Eadie-Hofstee plot (n=3) 
 
a. 
b. 
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4.6. PK and PD models of DEX in pregnant ewe model  
4.6.1. PK with nonlinear mixed effect (NLME) 
A total of 71 concentrations from pregnant ewe artery and 84 fetal arterial concentrations 
were used for the pharmacokinetic analysis of total DEX. A total of 24 maternal samples 
and 22 fetal samples were available to determine free DEX concentrations. Only two 
fetal free drug concentrations were lower than the LLOQ, so they were set to half of the 
LLOQ.  
4.6.1.1 PK modeling with maternal data of total DEX concentrations 
Of all the tested models, a two-compartment open model with first-order elimination best 
described the data (Figure 36). Compartments 1 and 2 described central and peripheral 
compartments. Mean (relative standard errors) parameter estimates of central volume of 
distribution (V), maternal peripheral volume of distribution (V2), elimination clearance 
(CL), intercompartmental clearance (Q) between V and V2 were 1.57 (27.8%) L/kg, 1.08 
(54.9%) L/kg, 30.1 (11.7%) mL/(kg*min) and 12.0 (32.1%) mL/(kg*min). The available 
data were insufficient to estimate intersubject variability for V2 and Q, and exclusion of 
these random effects had no influence on the −2 × log likelihood (-2LL). Residual 
variability was best described by a log-additive model and determined to be 0.372. Mean 
(relative standard errors) ωV and ωCL were 0.47 (59.9%) and 0.05 (79.3%), respectively.  
No apparent biases were observed by comparing population and individual predicted 
concentrations to observed concentrations (Figure 37). Diagnostic plots of population 
weighted residuals versus time and versus predicted concentrations did not show signs 
of significant bias (Figure 38).  
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Figure 36 PK model for total DEX concentration prediction in pregnant ewes.  
 
V: volume of the central maternal compartment 
V2 volume of the peripheral maternal compartment 
CL: elimination clearance from the central compartment 
Q: maternal intercompartmental clearance 
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Figure 37 Observed (DV) vs. predicted concentrations from the (a) population 
(PRED) and (b) individual (IPRED) fits 
 
 
 
a. 
b. 
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Figure 38 Population weighted residuals (CWRES) vs. (a) time and (b) predicted 
concentrations (PRED) 
 
 
a. 
b. 
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4.6.1.2 Protein binding model 
The relationship between the free and total concentration was evaluated because of 
potential changes in protein binding. Nonlinear protein-binding models could not be 
identified based on the available data and were not visually observable. The relationship 
between free and total DEX concentrations was best described using a constant binding 
model as follows: 
𝐶𝑡𝑜𝑡𝑎𝑙 =  
𝐶𝑓𝑟𝑒𝑒
𝑓𝑢
 
Where Ctotal represents the total drug concentration and fu represents the (estimated) 
fraction of free drug. 
4.6.1.3 PK modeling with addition of fetal data 
For fetal concentrations, several models were tested with fixed maternal parameters and 
then all the parameters of the integrated model were simultaneously estimated (Figure 
39). An effect compartment of negligible volume linked to the maternal circulation by 
first-order processes (Figure 39d) adequately characterized the fetal concentrations. 
The differential equations used are presented in the Appendix.  
Estimated parameters of the final model: central volume of distribution (V), maternal 
peripheral volume of distribution (V2), maternal elimination clearance (CL), 
intercompartmental clearance (Q) between V and V2, maternal elimination clearance 
(CL), maternal-to-fetal rate constant (Kmf), fetal-to-maternal rate constant (Kfm), maternal 
fraction of free drug (fu1) and fetal fraction of free drug (fu2) are summarized in Table 
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15.. The residual variability was best described by a log-additive error model. All fixed 
effect parameters were estimated with good precision (CV < 34%).  
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Figure 39 Schematic representations of pharmacokinetic models for the 
distribution of DEX to maternal central compartment, peripheral 
compartment and fetus after intravenous infusion administration to 
pregnant ewes.  
 
1, 2 and 3 denote maternal central compartment, peripheral compartment and fetal 
compartment, respectively. V: volume of the maternal central compartment; V2: volume 
of the maternal peripheral compartment; CL: elimination clearance from the central 
compartment; CL4: elimination clearance from the fetal compartment; Q and Q2: 
intercompartmental clearances; Kmf: maternal-to-fetal rate constant; and Kfm: fetal-to-
maternal rate constant. 
a. 
b. 
c. 
d. 
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Table 15 Parameter estimates from the PK model (of Fig. 39d) 
 
Description Parameter Units Estimate CV% 
Central Volume V L/kg 6.66 14.5 
Central Volume CL L/(kg*min) 0.07 20.8 
Periperheral Volume V2 L/kg 52.63 22.8 
Intercompartmental clearance Q L/(kg*min) 0.14 25.0 
Mother-to-fetus rate constant Kmf 1/min 0.06 34.0 
Fetus-to-mother rate constant Kfm 1/min 0.09 23.0 
Free fraction, mother fu1  
0.197 9.7 
Free faction, fetus fu2  
0.342 15.1 
Log-additive, total conc., mother σ1  
0.34 15.0 
Log-additive. total conc., fetus σ2  
0.57 22.7 
Log-additive, free conc., mother σ3  
0.41 20.1 
Log-additive, free conc., fetus σ4  
0.56 27.6 
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4.6.1.4 Evaluation and validation 
The model performance (of Fig. 39d) was evaluated by comparing the logarithm of 
population predicted concentrations to observed free and total plasma concentrations 
(Figures 40-41) and individual predicted concentration to observed free and total 
plasma concentrations (Figures 42-43). Population weighted residuals versus time 
(Figure 44) and versus predicted concentrations (Figure 45) were also plotted. No 
significant biases were observed in any of the diagnostic plots.  
Bootstrap validation was also employed to evaluate the model accuracy. The validation 
of the final model was performed with 100 runs and was successful for 98 runs. There 
was no significant difference between the estimates derived from the bootstrap and the 
predicted values from the Phoenix NLME PK analysis with original data. The standard 
errors derived from bootstrap were also comparable, except for the residual variability σ2 
and σ4. The values differ from the standard error estimated by the model because of the 
small size of the investigated subjects in this study. The mean values and standard 
errors are represented in Table 16. 
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Figure 40 Observed vs. population predicted free DEX concentrations from Fig. 39d in (a) pregnant ewe and (b) fetus 
a. b. 
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Figure 41 Observed vs. population predicted total DEX concentrations from Fig. 39d in (a) pregnant ewe and (b) fetus 
 
 
 
 
 
 
 
 
 
a. b. 
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Figure 42 Observed vs. individual predicted free DEX concentrations from Fig. 39d in (a) pregnant ewe and (b) fetus 
 
 
 
 
 
 
 
a. b. 
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Figure 43 Observed vs. individual predicted total DEX concentrations from Fig. 39d in (a) pregnant ewe and (b) fetus 
 
 
 
a. b. 
  
130 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 44 Population weighted residuals vs. time for (a) maternal free, (b) fetal free, (c) maternal total and (d) fetal total 
DEX from Fig. 39d. 
 
 
a. b. 
c. d. 
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Figure 45 Population weighted residuals vs. predicted concentrations for (a) maternal free, (b) fetal free, (c) maternal total 
and (d) fetal total DEX from Fig. 39d. 
a. b. 
c. d. 
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 Table 16 Pharmacokinetic parameter by bootstrap and comparison with (Fig. 39d) model parameters 
 
Parameter  Units 
Bootstrap  Model 
Mean CV% 95 % CI  Mean CV% 
V 
 
L/kg 6.05 21.7 4.08, 8.55  6.66 14.5 
CL 
 
L/(kg*min) 0.08 56.1 0.02, 1.99  0.07 20.8 
V2 
 
L/kg 53.36 70.4 8.71, 193  52.63 22.8 
Q 
 
L/(kg*min) 0.11 41.7 0.04, 2.09  0.14 25.0 
Kmf 
 
1/min 0.06 49.2 0.02, 0.14  0.06 34.0 
Kfm 
 
1/min 0.08 46.6 0.04, 0.22  0.09 23.0 
fu1 
 
 0.202 8.0 0.171, 0.241  0.197 9.7 
fu2 
 
 0.345 10.6 0.291, 0.397  0.342 15.1 
σ1 
 
 0.34 10.7 0.27, 0.43  0.34 15.0 
σ2 
 
 0.63 99.0 0.43, 0.64  0.57 22.7 
σ3 
 
 0.41 15.0 0.26, 0.48  0.41 20.1 
σ4 
 
 0.59 60.6 0.42, 0.65  0.56 27.6 
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4.6.2. PD modeling 
Blood pressure and heart rate at baseline, 30, 60, 90 and 120 min from four pregnant 
ewes and their corresponding four fetuses (three of the four ewes had twin pregnancies) 
were recorded to develop the PD modeling. Simulated free DEX concentrations from the 
PK model in Section 4.6.1 were used to develop the PD model. 
The relative cardiovascular changes (%) versus free DEX concentrations in pregnant 
ewe and fetus indicated the nonlinear relationship between PK and PD (Figure 46). A 
sigmoid Emax model where the effect equals to 0 at concentration 0, and the effect 
reaches Emax at infinite concentration, could be fitted to the pooled maternal heart rate 
and blood pressure (mean arterial pressure) response with an Emax of -52.6 ± 25.7%, 
EC50 of 14.5 ± 16.6 pg/mL and n of 0.67 ± 0.83 for the decrease in blood pressure in 
pregnant ewe. An Emax of -49.3 ± 4.7%, EC50 of 10.9 ± 6.12 pg/mL and n of 1.72 ± 1.56 
were derived for the decrease in heart rate (Table 17). In contrast, fetal cardiovascular 
response cannot be described by this model, and no apparent patterns were observed.  
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Figure 46 Cardiovascular changes (%) vs. predicted free DEX concentrations in 
(a) pregnant ewe and (b) fetus 
 
 
 
 
 
a. 
b. 
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Table 17 Pharmacodynamic parameter estimates in pregnant ewe 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameters 
Mean Arterial Pressure Heart Rate 
Mean ± SD CV (%) Mean ± SD CV 
Emax (%) -52.6 ± 25.7 48.8 -49.3 ± 4.7 9.6 
EC50 (pg/mL) 14.5 ± 16.6 113.9 10.9 ± 6.1 55.9 
n 0.68 ± 0.83 124.1 1.72 ± 1.56 90.5 
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Chapter 5 Discussion 
 
 
5.1. LC-MS/MS assay for quantification of DEX in plasma 
Fetal safety is always a major concern when drugs are used in pregnant women, and the 
potential risk of DEX on fetuses is poorly defined. Without the knowledge of the 
maternal-fetal pharmacokinetics and placental transfer of DEX during pregnancy, 
fetuses may suffer from adverse effects when DEX is used during pregnancy. The 
ethical challenge of experiments on human fetuses limits fetal safety studies. In our 
study, the pregnant ewe model has been used for maternal-fetal pharmacokinetics 
studies of DEX, in which the drug concentrations in maternal plasma and fetal plasma 
were monitored. However, a quantification assay was not readily available for DEX in 
these samples when we initiated the project.  
Methods for the quantification of DEX in humans have been reported, which include 
radioreceptor assays (Bol CJ et al., 1997), gas chromatography with tandem mass 
spectrometry (GC-MS) (Hui YH et al., 1997), HPLC-MS/MS (Ji QC et al., 2004; Lee JI et 
al., 2007; Li W et al., 2009) and UPLC-MS/MS (Inoue K et al., 2013). The radioreceptor 
assay was developed to quantify DEX concentration in rat plasma with an LLOQ of 24 
pg/mL, but the use of radioactive materials could be hazardous and this limits its 
widespread application (Bol CJ et al., 1997). The GC-MS method could determine DEX 
over concentration ranges of 0.1-40 ng/mL with an LLOQ of 50 pg/mL, but it was for 
human plasma and the procedure was laborious because of the need for chemical 
derivatization prior to quantification (Hui YH et al., 1997). One HPLC-MS/MS method 
could also be used to quantify DEX in human plasma with an LLOQ of approximately 20 
pg/mL, but it exhibited relatively low mean extraction recovery of 50.7-53.8% (Ji QC et 
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al., 2004). Recently, two more sensitive HPLC-MS/MS methods with the same LLOQ of 
5 pg/mL were published, one of which was used for pediatric plasma using small volume 
of 200 µL. It was based on a laborious solid-phase extraction and the matrix effect on 
ionization alteration has not been discussed (Lee JI et al., 2007). Another HPLC-MS/MS 
method for human plasma used a simple liquid-liquid extraction procedure with saturated 
sodium carbonate solution during the sample preparation in an attempt to improve the 
extraction efficiency (Li W et al., 2009). However, the saturated sodium carbonate is 
non-volatile and may be unfriendly to mass spectrometer. Another fast and stable 
isotope dilution UPLC-MS/MS method has also been developed for pediatric human 
plasma with the use of pricy isotopic IS (Inoue K et al., 2013). Therefore, considering the 
influence of matrix effects of biofluid among species (Gray NP et al., 2012), as well as 
procedure optimization, the development of a new and single assay is necessary in 
order to successfully monitor DEX concentrations in pregnant ewes and fetuses.  
The HPLC-MS/MS method that we developed fulfills the prerequisite for the 
pharmacokinetic characterization of DEX in pregnant ewe model, as it was sufficiently 
sensitive, specific, accurate and reliable for the determination of DEX in both pregnant 
ewes and fetuses. The LLOQ was 25 pg/mL for plasma using the 3200 QTRAP mass 
spectrometer, and a lower LLOQ of 10 pg/mL could be achieved with the 5500 QTRAP 
mass spectrometer. 
Good linear response was demonstrated in the selected range up to 5000 pg/ml. The 
sample preparation and liquid-liquid extraction procedures were simple, efficient and 
robust. Recovery efficiency of this method from plasma was concentration-independent. 
The overall recoveries of DEX were 82.9-87.2% and 86.2-89.7% for maternal plasma 
and fetal plasma, respectively. The percentage matrix factors in maternal plasma and 
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fetal plasma were less than 120%, indicating that the matrix components do not 
significantly influence the HPLC-MS/MS ionization signal. The variation observed in 
matrix effect reflected the variable concentrations of endogenous components in these 
biological matrices. However, the evaluation of the slopes of the calibration lines from six 
different sources of plasma confirmed that the matrix effects were consistent and posed 
no significant concerns on the DEX determination in different lots of biomatrices 
(Matuszewski BK, 2006). In the pharmacokinetic application, the developed and 
validated assay enables the quantification of DEX concentrations in maternal plasma 
and fetal plasma with the single assay protocol. This assay can be easily modified to 
quantify DEX in plasma protein binding and microsome metabolism studies.  
5.2. Pharmacokinetics of DEX in pregnant ewe and fetus 
Ethical concerns preclude adequate study of in vivo pharmacokinetics and 
transplacental transfer of DEX in human pregnancy. Our study addresses this 
knowledge gap and also provides information on the pharmacokinetics of DEX in the 
third-trimester pregnant ewe model for the first time. 
The current recommended dose of DEX in the clinical trials for sedation in the adult 
intensive care unit is a loading dose of 1 μg/kg over 10 min followed by a maintenance 
infusion of 0.2 to 0.7 μg/kg/h. However, the use of doses up to 1.5 μg/kg/h may be 
necessary for procedural sedation and have also been reported in various settings 
based on clinical requirement (Pandharipande PP et al., 2007; Riker RR et al., 2009; 
Pandharipande PP et al., 2010). In this work, the dose used was a loading dose of 1 
μg/kg for 10 min followed by an-hour infusion dose of 1 μg/kg/h. The dose is clinically 
relevant, as it is equivalent to a human dose of approximately 0.97 μg/kg for pregnant 
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women, with a reference body weight (80 kg) based on the power equation from FDA 
Guidance for Industry (FDA Guidance for Industry, 2005), where the human equivalent 
dose (HED) = animal dose (1 μg/kg) * [animal weight (72.84 kg) ÷ human weight (80 
kg)]0.33. The recommended weight gains with normal body weight in human pregnancy 
are 20, and 11.3-15.9 kg for single and twin pregnancy, respectively.  
The individual DEX PK in pregnant ewe and each fetus of twin pregnancy were analyzed 
by the non-compartmental model with maternal and fetal arterial concentrations. At 10 
min-infusion after administration to pregnant ewes, DEX concentrations in fetal artery 
were detectable, reflecting a rapid placental transfer into the fetal circulation. The rapid 
decline of the maternal DEX concentration after the end of infusion of DEX, reflecting a 
continuous distribution, probably to a peripheral compartment, as DEX has been 
reported to be best described by a two-compartment PK model in the human adult (Lee 
S et al., 2012; Flexman AM et al., 2014), children (Petroz GC et al., 2006; Diaz SM et al., 
2007; Potts AL et al., 2009), infant (Su F et al., 2010) and non-pregnant rat (Bol CJJG et 
al., 1997). 
The following much slower decline up to 1 h post the end of infusion was related to the 
overall elimination of DEX. In contrast, the DEX concentrations were sustained in the 
fetus without further dosing.  
A limitation of this work is the sparse sampling from a small number of subjects studied; 
8 pregnant ewes and 12 fetuses. A large intersubject variability in DEX concentrations 
was noticed during infusion in pregnant ewes. One pregnant ewe with very high 
concentrations in maternal vein during infusion was observed. This may explain the 
large inter-subject variability. Half of the ewes studied had twin pregnancies; while this 
may be considered to be a limitation, the inclusion of twin pregnancies should not affect 
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the plasma concentrations of DEX, as a previous study examining medetomidine levels 
suggested similar plasma concentrations in both twin and singleton ewe pregnancies 
(Musk GC et al., 2012). While the ewes received anesthesia induced by isoflurane in 
addition to DEX during the entire surgery, evidence has demonstrated that the 
pharmacokinetics of DEX is not influenced by isoflurane anesthesia (Thornton C et al., 
1999). The decreased cardiac output that may occur with increasing DEX concentrations 
may result in a corresponding decrease in elimination clearance, but the extent of this 
decrease is not significant and is unlikely to be clinically relevant (Dutta S et al., 2009).  
Despite these limitations, we have established the concentration-time profiles of DEX in 
pregnant ewes and fetuses and derived estimates of PK parameters with non-
compartmental analysis. We found that approximately 23% of systemic exposure (AUC) 
in the pregnant ewe crossed the placenta into fetal circulation which agrees with the 
transplacental transfer observed by Ala-Kokko and colleagues in the isolated human 
placenta model (Ala-Kokko TI et al., 1997). However, in the isolated placenta model, it 
remained unclear if the amount of DEX that crossed the placenta could exert 
hemodynamic effects on the fetus.  
5.3. Pharmacodynamics of DEX in pregnant ewe and fetus 
In our study, using the ewe model, we observed that the amount of DEX that crossed the 
placenta to the fetus did decrease the fetal heart rate, but the values remained within 
normal limits. This finding also lends support to El-Tahan’s study in which babies 
delivered via cesarean section during which mothers had received DEX, were delivered 
with normal APGAR scores (which are used to evaluate the effects of obstetric 
anesthesia on newborn babies) (El-Tahan MR et al., 2012).  
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Prior to the administration of DEX to the pregnant ewes and fetuses, the baseline mean 
arterial pressures and heart rate were within normal range for sheep (Cissik JH et al., 
1991; Booth LC et al., 2009). Following DEX administration in our study, significant 
hypotension and bradycardia was observed in the pregnant ewes with minimal change in 
hemodynamic parameters in the fetal lamb compared to baseline. These findings are 
similar to the findings by Uemura and colleagues where DEX had minimal effects on the 
fetal lamb (Uemura K et al., 2012). However, concurrent fetal drug levels were not 
obtained in their study. Our study provides conclusive evidence that while DEX 
administration to the pregnant ewe results in bradycardia and hypotension, the quantity 
that crosses the placenta into the fetal circulation is insufficient to exert similar 
hemodynamic effects in the fetus. 
The delineation of DEX pharmacokinetics in the fetus, determination of the amount of 
drug that crosses the placenta and also the trend of the effect the drug has on the fetal 
lamb provides an aggregate of information which will be helpful to practitioners who 
desire to administer DEX in pregnancy. 
The increase in fetal arterial oxygen tension noted between baseline and 60 min after 
completion of one hour infusion is consistent with previous documentation of a transient 
increase in fetal systemic oxygenation as a result of general anesthesia in the maternal 
ewe (McClaine RJ et al., 2005). The use of 2% isoflurane in oxygen in our study may 
also account for the observed increase in oxygenation. The worsening fetal metabolic 
acidosis observed after DEX infusion in our study may be related to impaired uterine 
perfusion following maternal hypotension. Maternal hypotension was not treated per 
study protocol. The possibility of fetal acidosis developing as a result of untreated 
  
142 
 
hypotension should be taken into consideration with the use of DEX, and hypotension 
should be treated accordingly. 
Clonidine, another α2-adrenergic agonist, when administered to the pregnant ewe, 
exerted bradycardia and hypoxemia in both ewe and fetus without associated 
hypotension (Eisenach JC et al., 1989). In contrast, in our study, DEX exerted significant 
bradycardia in the mother but the amount of DEX crossing the placenta was insufficient 
to exert a similar effect in the fetus. Similar to the clonidine study, we noted a decrease 
in fetal arterial pH at one hour following the end of DEX infusion. While we did not 
specifically measure uterine blood flow, we speculated that the observed acidosis in the 
fetal lamb in our study was due to potentially decreased uterine blood flow occurring as 
a result of hypotension in the maternal ewe. 
Our studies were performed in anesthetized animals in contrast to the chronically 
instrumented animal models used by other groups (Eisenach JC et al., 1989; Uemura K 
et al., 2012). There is a theoretical concern that the hemodynamic effects noted in our 
study may be a summative effect of both DEX and isoflurane. However, our 
hemodynamic findings were similar to that in the non-anesthetized model used by 
Uemura et al in which isoflurane was not used (Uemura K et al., 2012). The combination 
of general anesthesia and DEX in our study did not result in significant hemodynamic 
perturbations in the fetus. 
In pregnant women undergoing the ex utero intrapartum therapy (EXIT) procedure near 
term, high concentrations of volatile anesthetic agents are used (Garcia PJ et al., 2011). 
There is evidence that supplemental intravenous anesthetics decrease volatile 
anesthetic-induced depression of the fetal hemodynamics (Boat A et al., 2010). In our 
study, DEX was administered in concert with volatile anesthetic agents but with minimal 
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fetal hemodynamic compromise. However, volatile anesthetic agents used during the 
EXIT procedure may be administered at higher levels than that used in our study and in 
those settings, the combined hemodynamic effect with DEX may be detrimental. DEX 
should therefore be used with caution as a supplemental anesthetic for the EXIT 
procedure. 
5.4. Plasma protein binding assay 
Fetal exposure, which is related to fetal free drug concentrations, is affected by maternal 
dose and duration of exposure, maternal drug disposal, placental transfer, and fetal drug 
disposal. The factors affecting fetal drug exposure include molecular size and lipid 
solubility of the drug molecule, the plasma protein binding of the drug, and the relative 
pH gradients across placenta (Mihaly GW et al., 1983; Kumar S et al., 2000). The 
placenta is made up of lipid membranes between the maternal and fetal sides. 
According to the membrane permeability, compounds with lower molecular weight and 
higher lipid solubility can easily cross placenta, whereas the high degree of maternal 
plasma binding or ionization obstruct this process. In addition, phase I drug metabolites 
can be expected to cross the placenta, though more slowly than the parent compound, 
whereas phase II metabolites (conjugates) are highly polar and their placental transfer is 
negligible (Borrisud M et al., 1985; Wang LH et al., 1986). 
As DEX is a small molecule and has high lipid solubility, it can easily cross the placenta. 
An in vitro perfusion study has shown that DEX enters the fetal circulation rapidly but 
with a lower transfer rate comparing to less lipophilic clonidine (Ala-Kokko TI et al., 
1997). This phenomenon has also been observed for other highly lipophilic drugs using 
perfused human placenta, indicating the impact of protein binding on placental transfer 
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(Schneider H et al., 1988; Zakowski MI et al., 1994; Ala-Kokko TI et al., 1995; Johnson 
RF et al., 1995). In addition, high drug protein binding can contribute to the low volume 
of distribution and clearance for drugs. Moreover, large plasma protein bound 
components in the fetal compartment may retard the equilibrium by allowing less amount 
of drug to transfer back from fetus to mother.  
DEX is highly bound to albumin and α1-acid glycoprotein. The extents of plasma protein 
binding in humans, rats and dogs are 94%, 88% and 93%, respectively (Precedex 
injection label). However, no information is available regarding to the protein binding in 
the pregnant ewe model. Therefore, plasma protein binding factor should be evaluated 
to understand the differences in drug disposition and placental transfer between 
pregnant ewes and fetuses. Free drug concentration is ultimately responsible for the 
characterization of the placental transfer to rationalize the observed pharmacological 
effect.  
Two of the most commonly used methods for protein binding measurements are 
ultrafiltration and equilibrium. Many researchers have used ultrafiltration devices for the 
plasma protein binding measurement as ultrafiltration is a simple and rapid method in 
which centrifugation forces the buffer containing free drugs through the size exclusion 
membrane and achieves a fast separation of free from protein-bound drug molecules.  
The major concern of this method is nonspecific binding of the drugs on filter membrane 
and plastic devices. Equilibrium is less susceptible to experimental artifacts, but it is time 
consuming and it requires substantial equilibration time (3-24 h) at 37 °C. The 
degradation of DEX due to the duration of exposure to 37 °C has not yet been 
evaluated. Therefore, ultrafiltration devices were employed in our study and nonspecific 
binding was determined to correct the plasma protein binding.  
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We found that the fetus has about 15% less plasma protein binding than that in the 
pregnant ewe, which can be explained by lower protein concentrations and lower binding 
affinity in the fetus comparing to those in pregnant ewes (Syme MR et al., 2004). In 
humans, maternal and fetal albumin and α1-acid glycoprotein levels change continuously 
during pregnancy. As the gestational age increases, the maternal albumin and α1-acid 
glycoprotein concentrations decrease, whereas fetal albumin and α1-acid glycoprotein 
concentrations increase. The (fetal/maternal) concentration ratio of albumin increases 
from 0.38 at 12-15 weeks to 1.2 after 35 weeks of gestation, while the fetal/maternal 
concentration ratio of α1-acid glycoprotein increase from 0.1 at 10 weeks to 0.3-0.4 at 
term pregnancy (Hamar C et al., 1980; Wood M et al., 1981; Krauer B et al., 1984). In 
addition, differential structures in albumin forms between pregnant women and fetuses 
have suggested that maternal albumin exhibits a higher affinity for local anesthetics 
(Krasner J et al., 1973; Wallace S, 1977). Moreover, competing binding between drugs 
and endogenous ligands may contribute to the protein binding differences between 
pregnant women and fetuses (Ridd MJ et al., 1983; Nau H et al., 1984). However, the 
differential plasma protein binding between pregnant women and fetuses are primarily 
due to the difference in plasma protein concentrations between pregnant women and 
fetuses, rather than other factors (Hill MD et al., 1988; Syme MR et al., 2004).   
We have also observed a lower plasma protein binding in pregnant ewes compared to 
that in non-pregnant humans, rats and dogs, but the plasma protein binding of DEX in 
non-pregnant sheep has not been reported thus making the comparison difficult. 
Species difference in plasma protein binding kinetics has been demonstrated, especially 
for α1-acid glycoprotein binding of basic compounds (Belpaire FM et. al., 1984; Hill MD 
et. al., 1989; Son DS et. al., 1998; Huang Z et. al., 2013). Additionally, it is known that 
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there is a decrease in protein binding during pregnancy due to the decreased albumin 
and α1-acid glycoprotein concentrations (Syme MR et al., 2004).  
5.5. UGT metabolism of DEX in pregnant ewe and fetus 
DEX undergoes almost complete biotransformation through direct glucuronidation and 
CYP450 metabolism in humans. Direct N-glucuronidation at the imidazolate nitrogens is 
the major metabolic pathway (Precedex injection label), and UGT1A4 (for lower-affinity 
reaction) and UGT2B10 (for high-affinity reaction) have been suggested to be 
responsible for the DEX N-glucuronidation reaction (Kaivosaari S et al., 2008). In 
contrast, in rat liver microsomes, DEX N-glucuronidation was barely detectable. Dog 
liver microsomes can form N-glucuronides but at a lower efficiency than human liver 
microsomes. The metabolic profiles for pregnant ewe model have not been investigated.  
In the present study, glucuronidation metabolites of DEX were undetectable after the 
incubation with placental microsomes and hepatic microsome preparations from 
pregnant ewe and fetus, respectively, for up to 24 hr. This indicated that direct N-
glucuronidation is a negligible pathway in the pregnant ewe model which differs from that 
in humans. Chiu and Huskey (Chiu et al., 1998) have reported that N-glucuronidation 
exhibits marked differences across species. The N-glucuronidation rates of aromatic N-
heterocycles in humans are typically much higher than in animals, due to the activity of 
two enzymes, UGT1A4 and UGT2B10 (Kaivosaari S et al., 2011). Because of the 
diverse structures of aromatic N-heterocycles, this difference in N-glucuronidation across 
species is largely compound-dependent. Moreover, to date only six UGT isoforms have 
been identified in adult sheep liver including UGT1A1, UGT1A3, UGT1A4, UGT1A6, 
UGT1A9 and UGT2B7; UGT2B10 isoform is not detectable (Pretheeban M et al., 2011), 
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explaining the negligible DEX N-glucuronidation observed in pregnant ewe liver 
microsomes. Furthermore, the critical amino acid residue of UGT1A4 in human (Pro40) 
is different from that in sheep (His40) (Kubota T et. al., 2007; Pretheeban M et al., 2011). 
Therefore, while DEX N-glucuronides are formed efficiently in humans, pregnant ewes 
appear to lack the ability to conjugate the aromatic N-heterocycles.  
Different from UGT-mediated metabolism of DEX via N-glucuronidation, genistein 
primarily undergoes O-glucuronidation by UGT1As (UGT1A1, 1A8, 1A9 and 1A10). In 
this study, we were able to determine the differential UGT activities in hepatic 
microsomes between pregnant ewe and fetus by a kinetic study with genistein as a 
typical UGT substrate. The reaction kinetic data for genistein showed biphasic kinetics in 
which two isoforms with different kinetic behaviors were responsible for the 
glucuronidation. For the high-affinity reaction of the biphasic kinetics, the affinity in 
pregnant ewe and fetus is similar whereas pregnant ewe has 17 times higher capacity 
than that in fetus.  
It is well known that the fetus has a greatly reduced metabolizing enzyme capacity 
compared to adults and some enzymes do not appear to be expressed at all in the fetus. 
Studies have indicated both phase I and phase II metabolism can occur in human fetal 
liver (Krauer B et al., 1991; Hines RN et al., 2002; McCarver DG et al., 2002). The 
markedly lower activity of UGTs in fetuses than in adults has been suggested to be 
caused by the low transcripts (Strassburg CP et al., 2002; Izukawa T et al., 2009; 
Ekström L et al., 2013). No UGT transcripts were detected in two fetal liver samples at 
20 weeks’ gestation in a study to analyze expression of UGT1A and UGT2B genes and 
hepatic glucuronidation activity in human fetal liver (Strassburg CP et al., 2002).  
Ontogenesis of UDP-glucuronosyltransferase enzymes (UGTs) has been determined in 
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sheep and showed that mRNA levels of UGT1A6, UGT1A9 and UGT2B7 genes are 
expressed in fetal livers, but the levels are lower in the fetus than in the pregnant ewe 
(Pretheeban M et al., 2011).  
5.6. PK and PD modeling of DEX in pregnant ewe and fetus 
Free and total DEX PK in maternal and fetal concentrations was satisfactorily described 
by the proposed compartmental model. Data for fetal arterial blood samples were used 
due to the sparse samples collected from fetal vein (only 19 concentrations versus 62 
concentrations from arterial blood samples) and similar concentration profiles observed 
in fetal arterial and venous blood samples. The rate constants of distribution and 
elimination were 0.082 min-1 (= Kmf + Q/V) and 0.011 min
-1 (= CL/V) from pregnant ewe, 
respectively. This reflected the rapid placental transfer into the fetal circulation. The rapid 
decline of the maternal DEX concentration post the end of infusion demonstrated a 
continuous distribution to a peripheral compartment, probably the placenta. The 
following much slower decline was for the overall elimination of DEX. In contrast, the 
DEX concentrations were sustained with a longer t1/2 in the fetus even without further 
dosing. Despite the small number of subjects in this studied for PK analysis with NLME 
approach, all structural parameters estimated from the developed model were of 
adequate precision (i.e. CV < 34 %).  
The changes in blood pressure and heart rate in pregnant ewes were best fitted by the 
sigmoid Emax model. In the literature, the sigmoid Emax model was also used to describe 
the PK/PD relationships of DEX concentrations with blood pressure and heart rate 
effects in adult rats (Bol CJJG et al., 1997). The CV% in EC50 and n derived from the PD 
model is relatively large mainly due to the few datum points available at the low DEX 
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concentrations. This could be considered as one of the limitations to develop the PD 
model with the current data. Usually, the PK concentrations selected should cover the 
range of 3-fold EC50 in order to adequately describe the PK/PD relationship in the slope 
phase. Another limitation of this study is the lack of control experiments, and evaluation 
of PD response with dose escalation. Therefore, further investigation of PK/PD 
correlation is warranted.  
5.7. Data extrapolation from pregnant ewe to pregnant women  
Extrapolation of data from pregnant ewes to pregnant women should be interpreted with 
extreme caution. Although the pregnant ewe has been a popular animal model for 
placental transfer studies, the nature of its placental structure differs from that of human 
placenta and the pregnant ewe placenta is less permeable for drug transfer. In our 
study, this effect should be less pronounced for DEX as it is a highly lipid soluble 
compound with a low molecular weight (Vertommen et al., 1995). In addition, placental 
blood flows are known to be similar between pregnant ewes and pregnant women.  
The developed PK and PD models in our study contribute to the current state of 
knowledge of DEX exposure and maternal-fetal cardiovascular response to DEX. 
Unfortunately, direct comparison of estimates from PK and PD models between 
pregnant ewe and pregnant women is not yet possible. To the best of our knowledge, 
data on PK/PD parameters of DEX in pregnant women are still unavailable as a 
reference for comparison. A previous case study reported the placental transfer of DEX 
in pregnant women who underwent caesarean delivery (Neumann MM et al., 2009).  A 
total dose of 1.84 μg/kg was administered intravenously over approximately 40 min. In 
that study, the concentrations in maternal vein, umbilical artery and umbilical vein were 
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710, 540 and 543 pg/mL, respectively, at the time of delivery (110 min). No bradycardia 
and hemodynamic changes were detected in the fetus. The finding of the fetal/maternal 
concentration ratio (0.76) is consistent with the fetal/maternal concentration ratio (0.77) 
reported by Ala-Kokko et al. using the isolated perfused human placenta with the same 
amount of albumin on both maternal and fetal sides (Ala-Kokko TI et al., 1997). In our 
study, the fetal/maternal concentration ratios were 0.59 and 0.69 at 130 and 250 min, 
respectively. The comparison between the case study in pregnant women and our study 
is still complicated and difficult as DEX doses, blood sampling times and metabolism 
pathways are different between the two models. Nevertheless, no significant fetal 
adverse effects were observed in either situation. The fetal arterial and venous 
concentrations were similar in the two species. The slightly lower fetal/maternal 
concentration ratio in pregnant ewe compared to that in pregnant women might be 
explained by the lower permeability of pregnant ewe placenta compared to that of 
human placenta.   
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Chapter 6 Summary 
 
The contribution of our study is the quantitative characterization of fetal exposure and 
cardiovascular response to maternal administration of DEX in the pregnant ewe model. 
We have demonstrated that  
 Our developed and validated LC-MS/MS method can be applied to quantify DEX 
concentrations in the pregnant ewe model. 
 DEX rapidly crossed the pregnant ewe placenta with a partition coefficient (Kfm) 
of 23% after pregnant ewe was given DEX at a clinically relevant dose. 
 The pregnant ewe has a rapid distribution and a relatively slow elimination after 
DEX administration. 
 Total drug concentrations ranged from 29.8 to 6197.9 pg/mL in pregnant ewes, 
and from 8 to 265 pg/mL in fetuses. 
 Plasma protein binding of DEX was concentration-independent over the PK 
relevant concentrations in the pregnant ewe model.  
 Fractions of unbound DEX (fu) in pregnant ewe and fetus were 19.6 ± 3.9 % and 
36.9 ± 4.8 % for PK samples, respectively, and 25.1 ± 4.8 % and 38.9 ± 3.2 % for 
DEX-spiked blank plasma samples. The fu is significantly lower in pregnant ewe 
(19.7 ± 1.9 %) than those in the fetus (34.2 ± 5.2 %) in the PK model predictions. 
The fetus has significantly less plasma protein binding. 
 The amount of DEX transferred from the pregnant ewe to the fetus did not result 
in fetal hypotension or significant bradycardia.  
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 Direct N-glucuronidation is a negligible pathway for DEX in pregnant ewes, which 
differs from that in humans. Therefore, the pregnant ewe model may not be a 
representative model for humans in DEX phase II metabolism.  
 Differential UGT enzyme capacity between pregnant ewe and fetus has been 
characterized. 
 Findings from this study support further studies to determine if DEX can be used 
clinically during pregnancy.  
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Appendix 
The differential equations connected with the model depicted in Figure 39d were as 
follows: 
 
A1 = - CL * C - Q * C + Q * C2 
A2 = Q * C - Q * C2 
C3 = Kmf * C - Kfm * C3  
C = A1/V 
C2 = A2/V2 
Ct1 = C/fu1 
Ct3 = C3/fu2 
CObs = Ct1 * exp(CEps1) 
CObs2 = Ct3 * exp(CEps2) 
CObs3 = C * exp(CEps3) 
CObs4 = C3 * exp(CEps4) 
V = tvV * exp(nV) 
CL = tvCL * exp(nCL) 
V2 = tvV2 * exp(nV2) 
Q = tvQ * exp(nQ) 
Kmf = tvKmf * exp(nKmf) 
Kfm = tvKfm * exp(nKfm) 
fu1 = tvfu1 * exp(nfu1) 
fu2 = tvfu2 * exp(nfu2) 
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